CA2115465A1 - Highly alkaline proteases, dna sequences encoding them and process for their production - Google Patents
Highly alkaline proteases, dna sequences encoding them and process for their productionInfo
- Publication number
- CA2115465A1 CA2115465A1 CA 2115465 CA2115465A CA2115465A1 CA 2115465 A1 CA2115465 A1 CA 2115465A1 CA 2115465 CA2115465 CA 2115465 CA 2115465 A CA2115465 A CA 2115465A CA 2115465 A1 CA2115465 A1 CA 2115465A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- replaced
- position corresponding
- highly alkaline
- glutamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091005658 Basic proteases Proteins 0.000 title claims abstract description 77
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 60
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 9
- 238000000034 method Methods 0.000 title description 34
- 230000008569 process Effects 0.000 title description 7
- 150000001413 amino acids Chemical class 0.000 claims abstract description 139
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 244000005700 microbiome Species 0.000 claims abstract description 16
- 238000005406 washing Methods 0.000 claims abstract description 11
- 235000001014 amino acid Nutrition 0.000 claims description 120
- 108091005804 Peptidases Proteins 0.000 claims description 118
- 239000004365 Protease Substances 0.000 claims description 109
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 82
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 37
- 239000004475 Arginine Substances 0.000 claims description 29
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 29
- 102000035195 Peptidases Human genes 0.000 claims description 27
- 239000003599 detergent Substances 0.000 claims description 22
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 18
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 18
- 235000004279 alanine Nutrition 0.000 claims description 18
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 17
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 17
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 16
- 235000013922 glutamic acid Nutrition 0.000 claims description 16
- 239000004220 glutamic acid Substances 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940088598 enzyme Drugs 0.000 claims description 10
- 239000007844 bleaching agent Substances 0.000 claims description 9
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000012190 activator Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- -1 builders Substances 0.000 claims description 2
- 108010065511 Amylases Proteins 0.000 claims description 2
- 102000013142 Amylases Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 108090000854 Oxidoreductases Proteins 0.000 claims description 2
- 102000004316 Oxidoreductases Human genes 0.000 claims description 2
- 108010059820 Polygalacturonase Proteins 0.000 claims description 2
- 235000019418 amylase Nutrition 0.000 claims description 2
- 229940025131 amylases Drugs 0.000 claims description 2
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 108010084185 Cellulases Proteins 0.000 claims 1
- 102000005575 Cellulases Human genes 0.000 claims 1
- 231100000350 mutagenesis Toxicity 0.000 abstract description 20
- 238000002703 mutagenesis Methods 0.000 abstract description 20
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 238000009472 formulation Methods 0.000 abstract description 8
- 239000013598 vector Substances 0.000 description 120
- 108020004414 DNA Proteins 0.000 description 64
- 230000035772 mutation Effects 0.000 description 45
- 239000013612 plasmid Substances 0.000 description 44
- 125000003275 alpha amino acid group Chemical group 0.000 description 40
- 239000012634 fragment Substances 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 40
- 239000013604 expression vector Substances 0.000 description 38
- 108091008146 restriction endonucleases Proteins 0.000 description 26
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 108091034117 Oligonucleotide Proteins 0.000 description 20
- 102000053602 DNA Human genes 0.000 description 18
- 210000004899 c-terminal region Anatomy 0.000 description 17
- 241000588724 Escherichia coli Species 0.000 description 16
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 16
- 241000193375 Bacillus alcalophilus Species 0.000 description 13
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 108020004682 Single-Stranded DNA Proteins 0.000 description 9
- 238000010276 construction Methods 0.000 description 8
- 229940035893 uracil Drugs 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 description 5
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 5
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- 241001288713 Escherichia coli MC1061 Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 241000194108 Bacillus licheniformis Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- XSVSPKKXQGNHMD-UHFFFAOYSA-N 5-bromo-3-methyl-1,2-thiazole Chemical compound CC=1C=C(Br)SN=1 XSVSPKKXQGNHMD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 240000007681 Catha edulis Species 0.000 description 1
- 235000006696 Catha edulis Nutrition 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 1
- 101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- UEKYKRQIAQHOOZ-KBPBESRZSA-N Pro-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)[O-])C(=O)[C@@H]1CCC[NH2+]1 UEKYKRQIAQHOOZ-KBPBESRZSA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011141 high resolution liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012418 sodium perborate tetrahydrate Substances 0.000 description 1
- 229940045872 sodium percarbonate Drugs 0.000 description 1
- IBDSNZLUHYKHQP-UHFFFAOYSA-N sodium;3-oxidodioxaborirane;tetrahydrate Chemical compound O.O.O.O.[Na+].[O-]B1OO1 IBDSNZLUHYKHQP-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Detergent Compositions (AREA)
Abstract
Abstract of the Disclosure Optimized highly alkaline proteases suitable for use in washing agent formulations in which the original amino acids have been replaced in two, three, four or five of the given positions by different, defined amino acids, and a process for preparing them using microorganisms transformed by mutated DNA sequences obtained by altering DNA sequences encoding highly alkaline protease produced by Bacillus species in specified positions by directed mutagenesis.
Description
2 1 1 ~
HIGHLY ALKAI-INE PROTEASES, DNA SEQUENCES
ENCODING THEM AND PROCESS FOR IHEIR PRODUCTION
FieldoftheInvention The present invention relates to improved highly alkaline proteases in which certain amino acids have been replaced, to D~A sequences which have been altexed by directed mutagenesis and which encode these improved ;`~
proteases, and to vectors which contain these DNA sequences.
The present invention likewise relates to microarganisms lo transformed with these vectors, to a process for preparing optimized highly alkaline proteases, and to washing agents ;~ (i.e. detergents) which contain these improved proteases.
Background of the Tnventior ;~ Highly alkaline proteases are valuable industrial ~` 15 products having advantageou~ uses, particularly in the ;
detergent industry, since they remove impurities which contain protein. In order to be active, these proteins must ~;
not only possess proteolytic activity under washing conditions (pH, temperature) but, in addition to this, also 2~-- must be compatible with other detergent constituents, i.e.
in combination with other enzymes, surfactants, builders, bleaching agents, bleaching agent activators, and other additives and auxiliary substances; that is they must be sufficiently stable towards these constituents and be -~
25 sufficiently active in their presence. - ~
Highly alkaline proteases are special enzymes which are ""',r,~,, ' obtained by cultivating microorganisms, in particular by cultivating Bacillus species, which, like, for example, Bacillus alcalophilus, produce the desired highly alkaline ~
".. . ,- ,.
- 1 - , .' '-,'''' - 2~4~
protease and secrete it into the culture medium, from which the protease can be isolated. These highly alkaline proteases differ from ordinary alkaline proteases which can be obtained by cultivating Bacillus species such as, in particular, B. subtilis, B. amyloliquefaciens and B.
. liche~iformis, for example.
A series of natural and arti~icially (recombinantly) altered alkaline and highly alkaline proteases are known in -the state of the art. Thus, proteases are described, for example in Patent Applications WO 91/00345, EP 328,229 and EP 415,296, whose amino acid sequences have been altered at a plurality of positions by targeted mutagenesis (point mutations). -Nevertheless, there still exists a need for novel highly alkaline proteases which have been further optimi~ed and which exhibit improved properties with regard to their washing performance or stability.
.. - - ~'.'', SummarY of the Invention An aspect of the present invention is to make available novel highly alkaline . ~
pr~teases having properties which were further improved, as well as DNA sequences, :
vectors and transformed microorganisms which were necessary for this purpose, by the process of the present invention for preparing these proteases.
2s The invention relates to highly alkaline proteases which are distinguished by the fact that they have an amino acid sequence which possesses at least 80% homology with the amino acid sequence given in Fig. 1 (SEQ ID NO:l) and differs from this latter amino acid sequence in two, three, four or five of the positions 42, 43, 114, 216 and 249 of ~;
Fig. 1 or in the homologous positions therewith, where, in - the case of a replacement at the positions concerned, '., , ~.
--` 2 1 1 ~
the amino acid located in position 42 is replaced by arginine, the amino acid located in position 43 is replaced by glutamine, the amino acid located in position 114 is replaced by arginine, the amino acid located in position 216 is replaced by -~
serine, g]utamine or alanine, the amino acid located in position 249 is replaced by glutamic acid.
Other and further advantages and features of the invention will be apparent to those skilled in the art from the following detailed description thereof, taken in conjunction with ~ ~ .
the accompanying drawings.
Brief Description of the Drawings The invention will be described in further detail with `
reference to the accompanying drawing figures wherein: ~ -Fig. 1 shows the DNA sequence of the AvaI/HindIII
fragment, containing the structuraI gene of the highly alkaline starting protease from Bacillus alcalophilus HAl, as well as the amino acid sequence of this starting protease;
Fig. 2 shows the restriction map of the plasmid 2S pCLEAN4;
Fig. 3 shows the DNA sequences of the synthetic oligonucleotides used for the directed mutagenesis, with indications of the recognition sites for individual ;~
restriction endonucleases which were eliminated or produced, whereby the nucleotide changes which were made in the ;~
original DNA sequence of the starting protease are -~
designated by indicating the altered nucleotides using small letters;
Fig. 4 shows the restriction map of the vector pCLMUTNl;
HIGHLY ALKAI-INE PROTEASES, DNA SEQUENCES
ENCODING THEM AND PROCESS FOR IHEIR PRODUCTION
FieldoftheInvention The present invention relates to improved highly alkaline proteases in which certain amino acids have been replaced, to D~A sequences which have been altexed by directed mutagenesis and which encode these improved ;`~
proteases, and to vectors which contain these DNA sequences.
The present invention likewise relates to microarganisms lo transformed with these vectors, to a process for preparing optimized highly alkaline proteases, and to washing agents ;~ (i.e. detergents) which contain these improved proteases.
Background of the Tnventior ;~ Highly alkaline proteases are valuable industrial ~` 15 products having advantageou~ uses, particularly in the ;
detergent industry, since they remove impurities which contain protein. In order to be active, these proteins must ~;
not only possess proteolytic activity under washing conditions (pH, temperature) but, in addition to this, also 2~-- must be compatible with other detergent constituents, i.e.
in combination with other enzymes, surfactants, builders, bleaching agents, bleaching agent activators, and other additives and auxiliary substances; that is they must be sufficiently stable towards these constituents and be -~
25 sufficiently active in their presence. - ~
Highly alkaline proteases are special enzymes which are ""',r,~,, ' obtained by cultivating microorganisms, in particular by cultivating Bacillus species, which, like, for example, Bacillus alcalophilus, produce the desired highly alkaline ~
".. . ,- ,.
- 1 - , .' '-,'''' - 2~4~
protease and secrete it into the culture medium, from which the protease can be isolated. These highly alkaline proteases differ from ordinary alkaline proteases which can be obtained by cultivating Bacillus species such as, in particular, B. subtilis, B. amyloliquefaciens and B.
. liche~iformis, for example.
A series of natural and arti~icially (recombinantly) altered alkaline and highly alkaline proteases are known in -the state of the art. Thus, proteases are described, for example in Patent Applications WO 91/00345, EP 328,229 and EP 415,296, whose amino acid sequences have been altered at a plurality of positions by targeted mutagenesis (point mutations). -Nevertheless, there still exists a need for novel highly alkaline proteases which have been further optimi~ed and which exhibit improved properties with regard to their washing performance or stability.
.. - - ~'.'', SummarY of the Invention An aspect of the present invention is to make available novel highly alkaline . ~
pr~teases having properties which were further improved, as well as DNA sequences, :
vectors and transformed microorganisms which were necessary for this purpose, by the process of the present invention for preparing these proteases.
2s The invention relates to highly alkaline proteases which are distinguished by the fact that they have an amino acid sequence which possesses at least 80% homology with the amino acid sequence given in Fig. 1 (SEQ ID NO:l) and differs from this latter amino acid sequence in two, three, four or five of the positions 42, 43, 114, 216 and 249 of ~;
Fig. 1 or in the homologous positions therewith, where, in - the case of a replacement at the positions concerned, '., , ~.
--` 2 1 1 ~
the amino acid located in position 42 is replaced by arginine, the amino acid located in position 43 is replaced by glutamine, the amino acid located in position 114 is replaced by arginine, the amino acid located in position 216 is replaced by -~
serine, g]utamine or alanine, the amino acid located in position 249 is replaced by glutamic acid.
Other and further advantages and features of the invention will be apparent to those skilled in the art from the following detailed description thereof, taken in conjunction with ~ ~ .
the accompanying drawings.
Brief Description of the Drawings The invention will be described in further detail with `
reference to the accompanying drawing figures wherein: ~ -Fig. 1 shows the DNA sequence of the AvaI/HindIII
fragment, containing the structuraI gene of the highly alkaline starting protease from Bacillus alcalophilus HAl, as well as the amino acid sequence of this starting protease;
Fig. 2 shows the restriction map of the plasmid 2S pCLEAN4;
Fig. 3 shows the DNA sequences of the synthetic oligonucleotides used for the directed mutagenesis, with indications of the recognition sites for individual ;~
restriction endonucleases which were eliminated or produced, whereby the nucleotide changes which were made in the ;~
original DNA sequence of the starting protease are -~
designated by indicating the altered nucleotides using small letters;
Fig. 4 shows the restriction map of the vector pCLMUTNl;
., .~ . . . ~
211~6~
Fig. 5 shows the restriction map of the vector pC~MUTC1;
Fig. 6 shows the restriction map of the vector pUBC132;
Fig. 7 shows the restriction map of the vector pALlP;
Fig. 8 shows the restriction map of the expression vectors of the type pALlNC, used for expressing the highly alkaline proteases altered by mutation and for expressing the highly alkaline starting protease;
Fig. 9 shows the restriction map of the vector pALlN;
1~ and Fig. 10 shows the restriction map of the vector pALlC.
De~iled Description These highly alkaline proteases possess molecular weights of 26,000 to 28,000 g/mole, measured by SDS
polyacrylamide gel electrophoresis against reference proteins of known molecular weight. Their pH optimum is for the most part within the range from 8 to 12.5, where pH
optimum is understood to mean that pH range in which the proteases exhibit maximum proteolytic activity. The 2~ proteases according to the invention exhibit good pH
stability.
In accordance with one preferred embodiment of the invention, the proteases have amino acid sequences at least 90~ homologous. in particular, however, at least 95~
homologous, to the amino acid sequence of Fig. 1 (SEQ ID
NO:1). As used herein, the phrase "homologous to the amino acid sequence of Fig. 1" refers to the degree of sequence correspondence or sequence similarity between the respective amino acid sequence and the amino acid sequence given in 3~ Fig. 1 (SEQ ID NO:l). In order to determine homology, the segments of the amino acid sequence of Fig. 1 and of the amino acid sequence to be compared with it which correspond to each other structurally are superimposed with each other such that the maximum structural correspondence is obtained ' - 3a -.
.
;;
between the amino acid sequences, with differences caused by deletion or insertion of individual amino acids being taken into account and compensated for by correspondiny displace~
ments of sequence segments. The number of amino acids which ~, . '' ' ' ~.-'~
' :~
.: " :. .
-~
' " . ':, : .' ;'',.''~,"". '' ~ '" ' ~., ~;'''' ''', . ..- . ...:
'; ' '.''.~ ~
- 3b - ;~
, .. ", .':
~ 2~1~46~
. . .
now correspond to each other in the sequences ("homologous positions"), based on the total number of amino acids contained in the sequence in Fig. 1, then gives the homology in ~. Divergences in the sequences can be due to variation, insertion or deletion of amino acids. Accordingly, in the highly alkaline proteases according to the invention, which proteases were obtained from proteases which were at least 80% homologous with Fig. 1, the amino acid positions designated with reference to Fig. 1 relate to the positions homologous therewith. Deletions or insertions in the proteases which are homologous to the sequence of Fig. 1 can lead to a relative displacement of the amino acid positions, so that the numerical position designations of the amino acid positions corresponding to each other in homologous stretches of amino acid sequences need not be identical.
In the highly alkaline proteases according to the invention, the amino acids originally located in the replacement positions must be replaced by different defined amino acids. Thus, the amino acid located in position 42 is replaced by arginine, the amino acid located in position 43 is replaced by glutamine, the amino acid located in position 114 is replaced by arginine, the amino acid located in position 216 is replaced by either serine, glutamine or alanine, and the amino acid located in position 249 is replaced by glutamic acid. The amino acids originally present in the replacement positions can, in this context, be replaced in two, three, four or five, preferably in two or three, of the aforementioned positions. Thus, the proteases according to the invention exhibit two, three, ;~ 30 four or five of the amino acid replacements N42R, I43Q, N114R, T249E, M216S or M216Q or M216A, based on the positions given in Fig. 1 or on a position homologous therewith. In this patent application, conventional nomenclature is used for designating the mutations in which the amino acids are designated by the single-letter code, with the original amino acid being placed before the --` 211~
. ' ~.
position number and the introduced amino acid being placed after the position number.
Preferably, the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 216 is replaced by serine, glutamine or alanine and either the amino acid located in position 43 is replaced b~ glutamine or the amino acid located in position 114 is replaced by arginine or the amino acid located in position 249 is replaced by glutamic acid.
Based on the positions given in Fig. 1, or the positions homologous therewith, the proteases according to the invention thus exhibit the amino acid replacements M216S or M216Q or M216A and either I43Q or N114R or T249E.
In accordance with another preferred embodiment the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 216 is replaced by serine, glutamine or alanine and the amino acid located in position 114 is replaced by arginine and either the amino acid located in position 42 is replaced by arginine or the amino acid located in position 43 is replaced by glutamine. Based on the positions given in Fig. 1, or positions homologous therewith, the protease according to the invention thus exhibits the two amino acid replacements M216S or M216Q or M216A and either N42R or I43Q.
In accordance with a further preferred embodiement, the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 43 is replaced by glutamine; the amino acid located in position 249 is replaced by glutamic acid, and either the amino acid located in position 114 is replaced by arginine or the amino acid located in position 216 is replaced by ` serine, glutamine or alanine. Based on the positions given in Fig. 1, or positions homologous therewith, the protease according to the invention thus possesses the three amino .. .,:
211~6~
.. . ~
acid replacements I43Q and T249E and either N114R or M216S
or M216Q or M216A.
In accordance with an additionally preferred embodiment the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 43 is replaced by glutamine; the amino acid located in position 114 is replaced by arginine; the amino acid located in position 249 is replaced by glutamic acid, and the amino acid located in position 216 is replaced by serine, glutamine or alanine. Based on the positions given in Fig. 1, or positions homologous therewith, the protease according to the invention thus exhibits the four amino acid replacements I43Q, N114R, T249E and M216S or M216Q or M216A.
Of the aforementioned preferred replacement combinations in the amino acid sequence of the highly alkaline proteases according to the invention, those are very particularly preferred in which the amino acid located in position 216 is replaced by glutamine. Based on the ~`~ position given in Fig. 1, or the position homologous therewith, this denotes the one amino acid replacement M216Q
~; in the sequence of the protease according to the invention.
In an additional, particularly preferred, embodiment, the highly alkaline proteases according to the invention have an amino acid sequence in which the amino acid located in position 114 is replaced by arginine, and either the ~- amino acid located in position 43 is replaced by glutamine or the amino àcid ~located in position 249 is replaced by glutamic acid. Based on the positions~given in Fig. 1, or positions homologous therewith, the protease according to the invention thus exhibits the two amino acid replacements N114R and either I43Q or T249E.
As regards their washing performance and their storage stability, the highly alkaline proteases according to the invention are clearly superior to the proteases in which the amino acids at the aforementioned positions have not been replaced by the amino acids named for each position. It is 2115~
.
surprising that a marked improvement in the properties can be achieved, in comparison to the starting protease, using the particular combination of the designated amino acids in the aforementioned positions of the amino acid sequence, with positive effects astonishingly being achieved in the combination of the stated amino acid replacements.
In order to obtain the proteases according to the invention, microorganisms are cultivated which have been transformed with an expression-vector which contains a 0 structural gene encoding the respective protease.
The invention therefore also relates to DNA sequences which encode highly alkaline proteases having the above~
described amino acid sequences.
The DNA sequences according to the invention are distinguished by the fact khat they encode a highly alkaline protease which exhibits an amino acid sequence which possesses at least 80% homology with the amino acid sequence given in Fig. 1 and differs from this sequence in two~
three, four or five of the positions 42, 43, 114, 216 and 249 of Fig. 1, or the positions homologous therewith, by, in the event of a replacement at the positions concerned, the amino acid located in position 42 being replaced by arginine, the amino acid located in position 43 being replaced by glutamine, the amino acid located in position 114 being replaced by arginine, the amino acid located in position 216 being replaced by serine, glutamine or alanine, the amino acid located in position 249 being replaced . ...
by glutamic acid.
Those DNA sequences according to the invention are preferred which encode highly alkaline proteases whose amino acid sequences exhibit a homology of more than 90%, in ~
35 particular, however, of more than 95%, with the amino acid --sequence of Fig. 1 (SEQ ID NO:l) and in which two, three, ~ i : ': . .
- 7 ~
~1~5~
four or five of the given positions are replaced. The DNA
sequences according to the invention can, in particular, encode proteases which exhibit the aforementioned amino acid replacements in their sequence, based on the positions in Fig. 1 or on positions homologous therewith.
In addition, the invention relates to washing and/or cleaning compositions which contain at least one highly alkaline protease according to the invention. Such washing and cleaning agents can, for example, be employed for cleaning surfaces in the hygiene and food product fields.
Preferably, the proteases according to the invention are used in detergent formulations for cleaning textiles or tableware. For this purpose, the invention makes available a group of novel highly alkaline proteases having individual properties which are superior to those of previously known proteases, in particular superior washing performance and/or superior enzyme stability, rom which group, depending on the properties (washing performance, temperature resistance, compatibility with other constituents) of the highly alkaline protease to be employed which are especially required, a protease according to the invention can be selected which is particularly suitable ~or the relevant special detergent formulation. The proteases according to the invention can be employed in detergent or cleaning formulations, e.g. in powdered detergents, compact detergents or liquid de~ergents, either individually or, if desired, also in combination with each other, optionally in combination with conventional detergent proteases or with other customary detergent enzymes, such as, for example, amylases, lipases, pectinases, nucleases, oxidoreductases, etc. The proteases according to the invention are used in the detergent formulations in customary amounts for detergent enzymes, in particular in quantities of up to 5 by weight (based on the dry weight of the total composition), preferably in a quantity of 0.2 to 1.5~ by weight.
i ~-`` 2 1 ~ 5 ~
In addition to the detergent enzymes mentioned above, the detergents of the invention mày contain any of the washing agent ingredients which are customary in the state of the art, such as surfactants, bleaching agents or builder substances, as well as customary amounts of other conventional auxiliary substances used in formulating detergents. The auxiliary substances include, for example, boosters, enzyme stabilizers, anti-redeposition agents and/or compatibility agents, complexing and chelating agents, lather regulators and additives, such as optical brightening agents, opacifying agents, corrosion inhibitors, anti-electrostatic agents, dyes, bactericides, bleaching agent activators and peracid bleaching agent pre-stages.
Thus, detergent formulations according to the invention contain, in a typical exemplary composition, based on dry matter, a) at least 1~ by weight of a surfactant or surfactant mixture, b) up to 40% by weight of a builder or builder mixture, c) up to 40~ by weight of a bleaching agent or bleaching agent mixture, preferably a perborate, such as sodium perborate tetrahydrate, sodium perborate monohydrate or sodium percarbonate, d) up to 3~ by weight of at least one protease according to the invention, and e) further constituents, such as auxiliary substances, etc., up to 100~ by weight.
The proteases according to the invention are particularly well suited for use in powdered dishwashing detergents, such as those customarily employed, for example, in automatic dishwashers.
Powdered detergent formulations can be formulated in a conventional manner. For this purpose, for example in powdered or compact detergents, the proteases according to the invention can be mixed in a known manner with the other components of the detergent formulation in the form of g _ -. .-_ 21~6~
granules, prills or pellets, and optionally also provided with surface coatings.
Due to their improved stability, the proteases according to the invention may also be employed very effectively in liquid detergents.
The invention further relates to a process for preparing an optimized highly alkaline protease according to the invsntion using a transformed microorganism which contains a vector having a DNA sequence which encodes an amino acid sequence which possesses at least 80% homology with the amino acid se~uence of the starting protease given in Fig. 1 (SEQ ID NO:1) and differs from this sequence in two, three, four or five, preferably two or three, of the positions 42, 43, 114, 216 and 249 of Fig. 1, with the amino acid located in position 42 being replaced by arginine, the amino acid located in position 43 being replaced by glutamine, the amino acid located in position 114 belng replaced by arginine, the amino acid located in position 216 being replaced by serine, glutamine or alanine, and the amino acid located in position 249 being replaced by glutamic acid. The transformed microorganism is cultured, and the improved highly alkaline protease is isolated from the culture medium.
In order to produce the microorganisms employed in the preparation procedure, the approach can be that a) the DNA sequence encoding the protease (i.e. the structural gene of the protease) is initially isolated from a suitable bacterium which produces a highly ` alkaline protease having an amino acid sequence I possessing at least 80%, preferably more than 90%, in particular, however, more than 95%, homology with the amino acid sequence of Fig. 1 (SEQ ID NO~
b) the nucleotide sequence of this DNA sequence is determined, c) mutations (point mutations) are produced in the DNA
sequence which is now known such that the mutated DNA
.
. .
2 1 1 ~ 11 6 .
sequence now encodes a highly alkaline protease in which amino acids of the original protease are replaced, in aforementioned positi.ons, by an amino acid designated for the res ective position, d) an expression vector is subsequently produced lncorporating the mutated DNA sequence, and e) the resulting expression vector is transformed into a suitable microorganism, which can be finally be employed for preparing the mutated, highly alkaline protease.
The structural genes which encode amino acid sequences of highly alkaline proteases having at least 80~ homology with the amino acid sequence given in Fig. 1 tSEQ ID NO~
can be obtained using known methods. To do this, the chromosomal DNA is isolated, for example, from a bacterium ~ donor bacterium"), in particular from a Bacillus species, ;~ which produces the highly alkaline protease, and this DNA is then partially hydrolysed using suitable restriction endonucleases. -The resulting restriction fragments of the donor D~A
can be fractionated according to size, for example by gel ; electrophoresis, and the fragments of the desired size then recombined with a suitable vector DNA. Advantageously, a plasmid is used as the vector, by means of which plasmid expression can be achieved of the foreign DNA introduced into the host organism employed.
Bacteria, preferably a Bacillus species, can be transformed with the in vitro recombined DNA (vector +
restriction fragments of the donor DNA), and the ; 30 transformants can then be selected in accordance with a known marker property of the vector DNA (e.g. neomycin resistance). Those transformants, among all the resulting transformants, which secrete the highly alkaline protease to ; an increased extent can be sought on protein-containing plates and then isolated. Finally, the plasmid DNA
introduced into such a transformant clone can then be . .
..~. . . ,.:
2115~
isolated from it. Subsequently, the plasmid, which includes the structural gene of the starting protease and additional DNA sequences from the donor DNA sequence, is cut with a number of different restriction endonucleases (restricted);
the resulting DNA fragments are separated according to size by gel electrophoresis, and a restriction map is constructed - on the basis of the banding pattern which has been found.
Knowledge of the restriction map of the plasmid makes it possible to excise from the latter, by cutting with selected restriction endonucleases, a DNA fragment from the donor DNA
sequence, which fragment essentially now only encompasses the structural gene for the highly alkaline protease, the associated pre- and pro-units, and the promoter unit required for expression of the gene.
15By reincorporating this donor DNA sequence, which has now been reduced in size, into a suitable vector, a new, replicable vector can be obtained whose ability to express the highly alkaline starting protease can be tested by transforming a bacterium, in particular a Bacillus species, with this vector, cultivating the resultant transformant and testing it for protease activity. The restriction map in Fig. 2 represents an example of such a reduced vector, which vector has the designation pCLEAN4.
In order to sequence the structural gene of the protease, the aforedescribed vector is first replicated in a suitable microorganism, and the protease gene is subsequently isolated. This gene is then sequenced in accordance with generally known methods for DNA sequencing ~`(e.g. by the method of Maxam and Gilbert, 1980, Methods in Enzymologyl Grossmann L., Moldave K., eds., Academic Press Inc., New York and London, Vol. 65, 499, or by the dideoxy chain termination method of Sanger and Brownlee 1977, Proc.
Natl. Acad. Sci. USA 74: 5473).
The elucldated nucleotide sequence can then be translated, using the genetic code, into the amino acid sequence of the protease.
":
.:
2 1 ~ 5 ~
' In accordance with the invention, the DNA sequence encoding the protease is mutated by replacement of the corresponding codons such that the mutated DNA sequence encodes an optimized highly alkaline protease which possesses an amino acid sequence in which, in two, three, four or five, preferably two or three, of the positions 42, 43, 114, 216 and 249 of the amino acid sequence in Fig. 1 (SEQ ID NO:l), or in one of the positions homologous therewith, the amino acid in question is replaced by one of the aforementioned amino acids.
The point mutations are introduced into the DNA
encoding the highly alkaline protease by means of known methods for directed mutagenesis. For this purpose, circular single-stranded DNA is produced from suitable vectors (phagemids), e.g. from pCLMUTN1 of Fig. 4 or pCLMUTC1 of Fig. 5, optionally with the assistance of a helper phage, which single-stranded DNA contains the whole of the DNA sequence encoding the protease or, preferably, only the DNA sequence in which the mutation is to be undertaken. A hybridizable synthetic oligonucleotide, which contains, at the desired point mutation site, a nucleotide structural unit which is selected such that the associated codon encodes one of the amino acids already indicated for the relevant position, e.g. arginine in position 114, is hybridized with this circular single stranded D~A. In ~ addition, the oligonucleotide is also altered, as compared - with the original nucleotide sequence which is to be hybridized, by one or a few further nucleotide structural units, such that, while the coding of the original amino acid sequence is preserved within the limits of the degeneracy of the genetic code, either a restriction site ; which may be present in the original nucleotide sequence is removed in the synthetic oligonucleotide, or else a further restriction site is introduced into the synthetic oligonucleotide. The removed or introduced restriction site is later used for distinguishing the mutated DNA sequencç
21~6~
from the starting-type DNA sequence usin~g appropriate restriction endonucleases. In a variant, uracylated single-stranded DNA is produced as the template in the process of directed mutagenesis and used for hybridization to the synthetic oligonucleotides. Once the reactions of the process of directed mutagenesis are complete, the uracil-containing DNA single strand, which served as the template for producing mutated DNA strands (vectors), can be removed by treatment with uracil N-glycosylase without any phenotypic selection of mùtants being required. The glycosylase treatment can be carried out either using the isolated en2yme or else with the aid of a suitable microorganism possessing uracil N-glycosylase activity and transformed with mutated vector DNA.
The completion of the partially double-stranded DNA
sequence obtained by hybridization to give the complete double strand is then carried out by adding the necessary nucleotides and using DNA polymerase and DNA ligase. The circular, double-stranded DNA sequence which is produced is subsequently transformed as a vector into a suitable microorganism. Subsequently, the mutated DNA sequences are identified by means of the unique restriction endonuclease recognition sites and isolated from the transformant. If uracylated single-stranded DNA is employed, the replication 25 is then undertaken in, for example, an E. coli strain which -~
preferentially replicates the mutated, non-uracylated DNA
strand of the double-stranded vector produced in the mutation process. This additionally facilitates selection of the mutated DNA vectors.
~30 The synthetic oligonucleotides which are required for ~` -the directed mutagenesis are prepared by known methods (e.g.
according to Beaucage S.L. and Caruthers M.H., 1981, Tetrahedron Letters 22: 1859-1862).
The circular, double-stranded DNA sequences which were obtained by the directed mutagenesis and which possess the introduced mutations represent mutated vectors from which, - 14 - ~
,: ,.'' ~ : ' :::
depending on the circumstances, the whole mutated protease structural gene or the mutated stretch of the protease structural gene can be excised by treating with appropriate restriction endonucleases and introduced ~subcloned~ into an appropriate expression vector. This expression vector is then used to transform appropriate microorganisms, e.g.
Bacil7us species, which are subsequently cultivated under suitable conditions for expressing and isolating the mutated highly alkaline proteases.
In a preferred embodiment of the invention, the whole structural gene is not employed for the directed mutagenesis, but rather only a stretch thereof in which the mutation is to be produced. For this purpose, the N-terminal or C-terminal half of the structural gene, for example, is excised, using appropriate restriction endonucleases, from the vector which is being used to replicate the structural genes and then subcloned into a suitable phagemid. In this way, vectors are obtained which either contain the N-terminal or the C-terminal half of the structural gene and which are first replicated adequately in a suitable microorganismj for example E. coli, and then ;~ ~ subjected to the aforedescribed directed mutagenesis. An advantage of the mutagenesis of stretches of the DNA of the structural gene is that shorter single-stranded DNA
sequences can be used and thus, following the step of hybridization to synthetic oligonucleotides, appreciably fewer nucleotides have to be added to the partial D~A double strand than is the case when using the entire DNA sequence.
This reduces the synthetic requirements and also the danger ,of undesired accidental mutations.
The mutated DNA sequences can be excised from the vector used for producing the mutations with the aid of appropriate restriction endonucleases and then incorporated into vectors possessing corresponding restriction sites, which vectors represent precursors of the actual expression vectors which are required for expressing the highly .
211~
alkaline protease. These vectors are constructed such that, in addition to the appropriate restriction sites (e.g.
consisting of a synthetic linker), they also already contain the regulatory sequences, signal sequences, promoter sequences, and the DNA sequences encoding the pre- and pro-units of the protease, which are required for expressing the protease in a host organism.
Subcloning a mutated DNA sequence into such a vector produces the actual expression vector for an optimized highly alkaline protease. The mutated DNA sequence is incorporated into this expression vector precursor in such a way that an expression vector which has an appropriate reading frame is obtained. Mutated stretches of the DNA
sequence encoding the protease, e.g. a C-terminal or a N-terminal stretch, can be incorporated into vectors which already contain the relevant remaining non-mutated, or, optionally, also mutated (production of multiple mutations) stretch; alternatively, the whole mutated DNA sequence encoding the protease can be incorporated into vectors which, prior to this, do not contain any stretches of this protease DNA sequence. Examples of such precursor vectors of an expression vector which already contain stretches of the protease gene are the vectors having the designations ; pALlN and pALlC, whose restriction maps are reproduced in 2S Fig. 9 and Fig. 10, respectively.
The expression vector precursors for the preferred variant of the invention (mutation in the N-terminal half or in the C-terminal half) can be obtained, for example, by restricting a Bacillus plasmid at an appropriate site and recombining it with a fragment of an E. coli plasmid which contains a marker and sequence parts which are important for replication. Subsequently, where appropriate, those restriction sites which would interfere with the later procedural steps are removed, for example by directed mutagenesis. A new vector is constructed from the resulting plasmid, which vector contains the DNA sequences from the ..
2~ 1 ~4 ~
Bacillus plasmid and the E. coli plasmid which are used for replication, DNA sequences for the promoter, DNA sequences which encode the pre-pro sequence of the protease (obtained, for example, from the plasmid pCLEAN4 of Fig. 2) and a synthetic linker. The restriction map of Fig. 7 represents an example of such a plasmid having the designation pALlP.
In this regard, the synthetic linker is selected such that, following cleavage with appropriate restriction endonucleases, the vector can be combined with the whole original or mutated DNA sequence encoding the mature protease, or with mutated or non-mutated stretches of the structural gene. In order to prepare an expression vector precursor, which, for example, is to be recombined with a mutated N-terminal half of the structural gene, the non-mutated, or optionally already mutated, C-terminal half of the structural gene, for example, is initially inserted, by means of cleaving the synthetic linker, into the vector which is constructed as above and which contains the said Bacillus and E. coli sequences, the promoter and the pre and pro sequences of the protease, as well as the synthetic linker. Subsequently, the mutated N-terminal half of the structural gene of the protease, which is still lacking, is inserted by means of cleaving the synthetic linker once again. In this way, a vector of the type pALlNC of Fig. 8 is obtained. The procedure for the reverse case is analogous.
In this case, the non-mutated, or optionally already mutated, N-terminal half is initially inserted into a vector and the mutated C-terminal half is incorporated at a later stage into the resulting vector, a vector of the t~pe pALlNC
of Fig. 8 likewise being obtained.
Appropriate bacteria, preferably Bacillus species, in particular Bacillus subtilis, B. licheniformis or B.
alcalophilus, are transformed with the above-described expression vectors. The transformants are subsequently cultured in a known manner and the highly alkaline protease 211~fi~
' .
which is formed is isolated from the culture medium. For this purpose, the expression vectors can be transformed either into bacteria which are still capable of forming indigenous protease, or else into protease-deficient bacteria ~which no longer form indigenous protease). In the case of host organisms which form indigenous protease, the highly alkaline protease accordins to the invention can, if desired, be freed from the indigenous proteases which have formed by subsequent purification operations, for example by high resolution liquid chromatography (HPLC). By contrast, such a purification step can be omitted in the case of protease-deficient host organisms, since these organisms are only ~or essentially only) capable of forming the protease according to the invention.
The following examples are intended to illustrate the invention in further detail without, however, limiting its scope.
Unless otherwise indicated, the methods described in Maniatis et al. (Maniatis et al. = T. Maniatis, E.F.
Fritsch, J. Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982) were generally employed.
Starting vectors used here are available commercially and on an unrestricted basis; otherwise, they can be ~; ~ 25 prepared, by known methods from available vectors.
The Bacillus alcalophilus strain employed in Example 1, and designated Bacillus alcalophilus HAl, was deposited on 28 July 1989 with the Deutsche Sammlung von Mikroorganismen (DSM) ~German Collection of Microorganisms) Braunschweig, Germany under the DSM number 5466.
- , :
~. .
' "~.:;
,: .
2~15~5 . .
Example 1: Preparation of a genomic DNA library from B.
alcalophilus and isolation of the gene for the highly alkaline starting protease.
Chromosomal DNA was isolated from the natural isolate 5 Bacillus alcalophilus HA1 (deposited with the German Collection of Microorganisms under the DSM number 5466) in accordance with the method of Saito et al. ~1963, Biochim.
Biophys. Acta. 72: 619-629) and then partially hydrolysed using the restriction endonuclease Sau3A. The restriction . ~.
~ '' .,,''-', :':
`
. .:
~ :
~ '~
.. .
~ , ,.
:
.:
2 ~
fragments were fractionated by electrophoresis on an agarose gel, and the fragments having a size of from 3 to 8 kilobases (KB) were isolated.
The isolated and size-selected DNA fragments from Bacillus alcalophilus HAl were recombined in vitro with plasmid pUB 110 vector DNA (obtained as described in Example 7).
For this purpose, the plasmid pUB110 was first restricted with the restriction endonuclease BamHI and then dephosphorylated using calf intestinal alkaline phosphatase.
Subsequently, 2 ~g of the restricted and dephosphorylated vector DNA were incubated at 16C for 24 hours together with 8 ~g of the Racillus alcalophilus DNA fragments in a total volume of 100 ~l and in the presence of T4 DNA ligase.
Protoplasts of the strain Baci71us subtilis BD224 were transformed with the resulting DNA, which had been recombined in vitro, in accordance with the method described by S. Chang and N. Cohen (1979, Mol. Gen. Genet. 168~
115). The transformants were selected on plates ; 20 containing neomycin and subsequently transferred to skimmed milk agar. Among 13,800 transformants which were examined, one was found which formed a distinctly larger aureole from proteolysis of the skimmed milk. The plasmid DNA was isolated from this clone in accordance with Maniatis et al. ~ ~ 25 The cloned fragment of B. alcalophilus DNA contained in this plasmid had a size of 4.1 KB and contained the entire information for the highly alkaline protease from Bacillus alcalophilus HAl.
In order to simplify the subsequent procedure, the 4.1 KB-sized DNA fragment was first reduced in size. To do l l , '' ' ' this, the recognition sites for restriction endonucleases located on the DNA fragment were identified by cleaving the plasmid with various restriction endonucleases and:~
fractionating the fragments of the restricted DNA by ~ `
electrophoresis on an agarose gel. A 2.3 KB-sized DNA
fragment, obtained by cleaving with the restriction ~: :
- 20 - ~
. . . ~ . , ' .
2~.:.5~
' !
endonucleases AvaI and HindIII, was identified which contained the complete information for the highly alkaline protease and which was used for the subsequent procedure.
For this, the above plasmid containing the 4.1 KB fragment was restricted with the restriction endonucleases AvaI and HindIII. The 2.3 KB-sized DNA fragment was isolated and ligated to the vector pUB131 (obtained as described in Example 7), which vector had likewise previously been cut with AvaI and HindIII.
The resulting plasmid, which was given the designation pCLEAN4, was introduced into the strain B. subtilis BD224.
The transformants were able to secrete the highly alkaline protease, indicating that the AvaI/HindIII fragment contains the complete structural gene for the highly alkaline protease from B. alcalophilus HA1. The restriction map of the plasmid pCLEAN4 is given in Fig. 2.
Example 2: Sequencing of the structural gene for the highly alkaline protease.
In order to prepare single-stranded DNA of the structural gene of the protease, the plasmid pCLEAN4 was cleaved with the restriction endonucleases AvaI and HindIII
and the approximately 2.3 KB-sized AvaI/HindIII DNA fragment (st~uctural gene of the protease) was introduced into the phagemids pBS (+) or pBS (-). The nucleotide sequence of the protease gene contained in the isolated single-stranded phagemids was determined by the dideoxy chain termination method of Sanger et al. (1977, Proc. Natl. Acad. Sci. USA
74: 5463) and by the method of base-speclfic chemical cleavage of the DNA single strand in accordance with Maxam et al. (1980, in Methods in Enzymology, Grossmann L., Moldave K., eds., Academic Press Inc., New York and London, Vol. 65, 499). The nucleotide sequence which was determined, and the deduced amino acid sequence of the protease, are yiven in Fig. 1. The start of the amino acid sequence of the mature highly alkaline protease, in position 211~65 1190 of the nucleotide sequence, wa~ determined by amino~
acid sequencing the N-terminal end of the highly alkaline protease.
211~6~
Fig. 5 shows the restriction map of the vector pC~MUTC1;
Fig. 6 shows the restriction map of the vector pUBC132;
Fig. 7 shows the restriction map of the vector pALlP;
Fig. 8 shows the restriction map of the expression vectors of the type pALlNC, used for expressing the highly alkaline proteases altered by mutation and for expressing the highly alkaline starting protease;
Fig. 9 shows the restriction map of the vector pALlN;
1~ and Fig. 10 shows the restriction map of the vector pALlC.
De~iled Description These highly alkaline proteases possess molecular weights of 26,000 to 28,000 g/mole, measured by SDS
polyacrylamide gel electrophoresis against reference proteins of known molecular weight. Their pH optimum is for the most part within the range from 8 to 12.5, where pH
optimum is understood to mean that pH range in which the proteases exhibit maximum proteolytic activity. The 2~ proteases according to the invention exhibit good pH
stability.
In accordance with one preferred embodiment of the invention, the proteases have amino acid sequences at least 90~ homologous. in particular, however, at least 95~
homologous, to the amino acid sequence of Fig. 1 (SEQ ID
NO:1). As used herein, the phrase "homologous to the amino acid sequence of Fig. 1" refers to the degree of sequence correspondence or sequence similarity between the respective amino acid sequence and the amino acid sequence given in 3~ Fig. 1 (SEQ ID NO:l). In order to determine homology, the segments of the amino acid sequence of Fig. 1 and of the amino acid sequence to be compared with it which correspond to each other structurally are superimposed with each other such that the maximum structural correspondence is obtained ' - 3a -.
.
;;
between the amino acid sequences, with differences caused by deletion or insertion of individual amino acids being taken into account and compensated for by correspondiny displace~
ments of sequence segments. The number of amino acids which ~, . '' ' ' ~.-'~
' :~
.: " :. .
-~
' " . ':, : .' ;'',.''~,"". '' ~ '" ' ~., ~;'''' ''', . ..- . ...:
'; ' '.''.~ ~
- 3b - ;~
, .. ", .':
~ 2~1~46~
. . .
now correspond to each other in the sequences ("homologous positions"), based on the total number of amino acids contained in the sequence in Fig. 1, then gives the homology in ~. Divergences in the sequences can be due to variation, insertion or deletion of amino acids. Accordingly, in the highly alkaline proteases according to the invention, which proteases were obtained from proteases which were at least 80% homologous with Fig. 1, the amino acid positions designated with reference to Fig. 1 relate to the positions homologous therewith. Deletions or insertions in the proteases which are homologous to the sequence of Fig. 1 can lead to a relative displacement of the amino acid positions, so that the numerical position designations of the amino acid positions corresponding to each other in homologous stretches of amino acid sequences need not be identical.
In the highly alkaline proteases according to the invention, the amino acids originally located in the replacement positions must be replaced by different defined amino acids. Thus, the amino acid located in position 42 is replaced by arginine, the amino acid located in position 43 is replaced by glutamine, the amino acid located in position 114 is replaced by arginine, the amino acid located in position 216 is replaced by either serine, glutamine or alanine, and the amino acid located in position 249 is replaced by glutamic acid. The amino acids originally present in the replacement positions can, in this context, be replaced in two, three, four or five, preferably in two or three, of the aforementioned positions. Thus, the proteases according to the invention exhibit two, three, ;~ 30 four or five of the amino acid replacements N42R, I43Q, N114R, T249E, M216S or M216Q or M216A, based on the positions given in Fig. 1 or on a position homologous therewith. In this patent application, conventional nomenclature is used for designating the mutations in which the amino acids are designated by the single-letter code, with the original amino acid being placed before the --` 211~
. ' ~.
position number and the introduced amino acid being placed after the position number.
Preferably, the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 216 is replaced by serine, glutamine or alanine and either the amino acid located in position 43 is replaced b~ glutamine or the amino acid located in position 114 is replaced by arginine or the amino acid located in position 249 is replaced by glutamic acid.
Based on the positions given in Fig. 1, or the positions homologous therewith, the proteases according to the invention thus exhibit the amino acid replacements M216S or M216Q or M216A and either I43Q or N114R or T249E.
In accordance with another preferred embodiment the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 216 is replaced by serine, glutamine or alanine and the amino acid located in position 114 is replaced by arginine and either the amino acid located in position 42 is replaced by arginine or the amino acid located in position 43 is replaced by glutamine. Based on the positions given in Fig. 1, or positions homologous therewith, the protease according to the invention thus exhibits the two amino acid replacements M216S or M216Q or M216A and either N42R or I43Q.
In accordance with a further preferred embodiement, the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 43 is replaced by glutamine; the amino acid located in position 249 is replaced by glutamic acid, and either the amino acid located in position 114 is replaced by arginine or the amino acid located in position 216 is replaced by ` serine, glutamine or alanine. Based on the positions given in Fig. 1, or positions homologous therewith, the protease according to the invention thus possesses the three amino .. .,:
211~6~
.. . ~
acid replacements I43Q and T249E and either N114R or M216S
or M216Q or M216A.
In accordance with an additionally preferred embodiment the highly alkaline protease according to the invention has an amino acid sequence in which the amino acid located in position 43 is replaced by glutamine; the amino acid located in position 114 is replaced by arginine; the amino acid located in position 249 is replaced by glutamic acid, and the amino acid located in position 216 is replaced by serine, glutamine or alanine. Based on the positions given in Fig. 1, or positions homologous therewith, the protease according to the invention thus exhibits the four amino acid replacements I43Q, N114R, T249E and M216S or M216Q or M216A.
Of the aforementioned preferred replacement combinations in the amino acid sequence of the highly alkaline proteases according to the invention, those are very particularly preferred in which the amino acid located in position 216 is replaced by glutamine. Based on the ~`~ position given in Fig. 1, or the position homologous therewith, this denotes the one amino acid replacement M216Q
~; in the sequence of the protease according to the invention.
In an additional, particularly preferred, embodiment, the highly alkaline proteases according to the invention have an amino acid sequence in which the amino acid located in position 114 is replaced by arginine, and either the ~- amino acid located in position 43 is replaced by glutamine or the amino àcid ~located in position 249 is replaced by glutamic acid. Based on the positions~given in Fig. 1, or positions homologous therewith, the protease according to the invention thus exhibits the two amino acid replacements N114R and either I43Q or T249E.
As regards their washing performance and their storage stability, the highly alkaline proteases according to the invention are clearly superior to the proteases in which the amino acids at the aforementioned positions have not been replaced by the amino acids named for each position. It is 2115~
.
surprising that a marked improvement in the properties can be achieved, in comparison to the starting protease, using the particular combination of the designated amino acids in the aforementioned positions of the amino acid sequence, with positive effects astonishingly being achieved in the combination of the stated amino acid replacements.
In order to obtain the proteases according to the invention, microorganisms are cultivated which have been transformed with an expression-vector which contains a 0 structural gene encoding the respective protease.
The invention therefore also relates to DNA sequences which encode highly alkaline proteases having the above~
described amino acid sequences.
The DNA sequences according to the invention are distinguished by the fact khat they encode a highly alkaline protease which exhibits an amino acid sequence which possesses at least 80% homology with the amino acid sequence given in Fig. 1 and differs from this sequence in two~
three, four or five of the positions 42, 43, 114, 216 and 249 of Fig. 1, or the positions homologous therewith, by, in the event of a replacement at the positions concerned, the amino acid located in position 42 being replaced by arginine, the amino acid located in position 43 being replaced by glutamine, the amino acid located in position 114 being replaced by arginine, the amino acid located in position 216 being replaced by serine, glutamine or alanine, the amino acid located in position 249 being replaced . ...
by glutamic acid.
Those DNA sequences according to the invention are preferred which encode highly alkaline proteases whose amino acid sequences exhibit a homology of more than 90%, in ~
35 particular, however, of more than 95%, with the amino acid --sequence of Fig. 1 (SEQ ID NO:l) and in which two, three, ~ i : ': . .
- 7 ~
~1~5~
four or five of the given positions are replaced. The DNA
sequences according to the invention can, in particular, encode proteases which exhibit the aforementioned amino acid replacements in their sequence, based on the positions in Fig. 1 or on positions homologous therewith.
In addition, the invention relates to washing and/or cleaning compositions which contain at least one highly alkaline protease according to the invention. Such washing and cleaning agents can, for example, be employed for cleaning surfaces in the hygiene and food product fields.
Preferably, the proteases according to the invention are used in detergent formulations for cleaning textiles or tableware. For this purpose, the invention makes available a group of novel highly alkaline proteases having individual properties which are superior to those of previously known proteases, in particular superior washing performance and/or superior enzyme stability, rom which group, depending on the properties (washing performance, temperature resistance, compatibility with other constituents) of the highly alkaline protease to be employed which are especially required, a protease according to the invention can be selected which is particularly suitable ~or the relevant special detergent formulation. The proteases according to the invention can be employed in detergent or cleaning formulations, e.g. in powdered detergents, compact detergents or liquid de~ergents, either individually or, if desired, also in combination with each other, optionally in combination with conventional detergent proteases or with other customary detergent enzymes, such as, for example, amylases, lipases, pectinases, nucleases, oxidoreductases, etc. The proteases according to the invention are used in the detergent formulations in customary amounts for detergent enzymes, in particular in quantities of up to 5 by weight (based on the dry weight of the total composition), preferably in a quantity of 0.2 to 1.5~ by weight.
i ~-`` 2 1 ~ 5 ~
In addition to the detergent enzymes mentioned above, the detergents of the invention mày contain any of the washing agent ingredients which are customary in the state of the art, such as surfactants, bleaching agents or builder substances, as well as customary amounts of other conventional auxiliary substances used in formulating detergents. The auxiliary substances include, for example, boosters, enzyme stabilizers, anti-redeposition agents and/or compatibility agents, complexing and chelating agents, lather regulators and additives, such as optical brightening agents, opacifying agents, corrosion inhibitors, anti-electrostatic agents, dyes, bactericides, bleaching agent activators and peracid bleaching agent pre-stages.
Thus, detergent formulations according to the invention contain, in a typical exemplary composition, based on dry matter, a) at least 1~ by weight of a surfactant or surfactant mixture, b) up to 40% by weight of a builder or builder mixture, c) up to 40~ by weight of a bleaching agent or bleaching agent mixture, preferably a perborate, such as sodium perborate tetrahydrate, sodium perborate monohydrate or sodium percarbonate, d) up to 3~ by weight of at least one protease according to the invention, and e) further constituents, such as auxiliary substances, etc., up to 100~ by weight.
The proteases according to the invention are particularly well suited for use in powdered dishwashing detergents, such as those customarily employed, for example, in automatic dishwashers.
Powdered detergent formulations can be formulated in a conventional manner. For this purpose, for example in powdered or compact detergents, the proteases according to the invention can be mixed in a known manner with the other components of the detergent formulation in the form of g _ -. .-_ 21~6~
granules, prills or pellets, and optionally also provided with surface coatings.
Due to their improved stability, the proteases according to the invention may also be employed very effectively in liquid detergents.
The invention further relates to a process for preparing an optimized highly alkaline protease according to the invsntion using a transformed microorganism which contains a vector having a DNA sequence which encodes an amino acid sequence which possesses at least 80% homology with the amino acid se~uence of the starting protease given in Fig. 1 (SEQ ID NO:1) and differs from this sequence in two, three, four or five, preferably two or three, of the positions 42, 43, 114, 216 and 249 of Fig. 1, with the amino acid located in position 42 being replaced by arginine, the amino acid located in position 43 being replaced by glutamine, the amino acid located in position 114 belng replaced by arginine, the amino acid located in position 216 being replaced by serine, glutamine or alanine, and the amino acid located in position 249 being replaced by glutamic acid. The transformed microorganism is cultured, and the improved highly alkaline protease is isolated from the culture medium.
In order to produce the microorganisms employed in the preparation procedure, the approach can be that a) the DNA sequence encoding the protease (i.e. the structural gene of the protease) is initially isolated from a suitable bacterium which produces a highly ` alkaline protease having an amino acid sequence I possessing at least 80%, preferably more than 90%, in particular, however, more than 95%, homology with the amino acid sequence of Fig. 1 (SEQ ID NO~
b) the nucleotide sequence of this DNA sequence is determined, c) mutations (point mutations) are produced in the DNA
sequence which is now known such that the mutated DNA
.
. .
2 1 1 ~ 11 6 .
sequence now encodes a highly alkaline protease in which amino acids of the original protease are replaced, in aforementioned positi.ons, by an amino acid designated for the res ective position, d) an expression vector is subsequently produced lncorporating the mutated DNA sequence, and e) the resulting expression vector is transformed into a suitable microorganism, which can be finally be employed for preparing the mutated, highly alkaline protease.
The structural genes which encode amino acid sequences of highly alkaline proteases having at least 80~ homology with the amino acid sequence given in Fig. 1 tSEQ ID NO~
can be obtained using known methods. To do this, the chromosomal DNA is isolated, for example, from a bacterium ~ donor bacterium"), in particular from a Bacillus species, ;~ which produces the highly alkaline protease, and this DNA is then partially hydrolysed using suitable restriction endonucleases. -The resulting restriction fragments of the donor D~A
can be fractionated according to size, for example by gel ; electrophoresis, and the fragments of the desired size then recombined with a suitable vector DNA. Advantageously, a plasmid is used as the vector, by means of which plasmid expression can be achieved of the foreign DNA introduced into the host organism employed.
Bacteria, preferably a Bacillus species, can be transformed with the in vitro recombined DNA (vector +
restriction fragments of the donor DNA), and the ; 30 transformants can then be selected in accordance with a known marker property of the vector DNA (e.g. neomycin resistance). Those transformants, among all the resulting transformants, which secrete the highly alkaline protease to ; an increased extent can be sought on protein-containing plates and then isolated. Finally, the plasmid DNA
introduced into such a transformant clone can then be . .
..~. . . ,.:
2115~
isolated from it. Subsequently, the plasmid, which includes the structural gene of the starting protease and additional DNA sequences from the donor DNA sequence, is cut with a number of different restriction endonucleases (restricted);
the resulting DNA fragments are separated according to size by gel electrophoresis, and a restriction map is constructed - on the basis of the banding pattern which has been found.
Knowledge of the restriction map of the plasmid makes it possible to excise from the latter, by cutting with selected restriction endonucleases, a DNA fragment from the donor DNA
sequence, which fragment essentially now only encompasses the structural gene for the highly alkaline protease, the associated pre- and pro-units, and the promoter unit required for expression of the gene.
15By reincorporating this donor DNA sequence, which has now been reduced in size, into a suitable vector, a new, replicable vector can be obtained whose ability to express the highly alkaline starting protease can be tested by transforming a bacterium, in particular a Bacillus species, with this vector, cultivating the resultant transformant and testing it for protease activity. The restriction map in Fig. 2 represents an example of such a reduced vector, which vector has the designation pCLEAN4.
In order to sequence the structural gene of the protease, the aforedescribed vector is first replicated in a suitable microorganism, and the protease gene is subsequently isolated. This gene is then sequenced in accordance with generally known methods for DNA sequencing ~`(e.g. by the method of Maxam and Gilbert, 1980, Methods in Enzymologyl Grossmann L., Moldave K., eds., Academic Press Inc., New York and London, Vol. 65, 499, or by the dideoxy chain termination method of Sanger and Brownlee 1977, Proc.
Natl. Acad. Sci. USA 74: 5473).
The elucldated nucleotide sequence can then be translated, using the genetic code, into the amino acid sequence of the protease.
":
.:
2 1 ~ 5 ~
' In accordance with the invention, the DNA sequence encoding the protease is mutated by replacement of the corresponding codons such that the mutated DNA sequence encodes an optimized highly alkaline protease which possesses an amino acid sequence in which, in two, three, four or five, preferably two or three, of the positions 42, 43, 114, 216 and 249 of the amino acid sequence in Fig. 1 (SEQ ID NO:l), or in one of the positions homologous therewith, the amino acid in question is replaced by one of the aforementioned amino acids.
The point mutations are introduced into the DNA
encoding the highly alkaline protease by means of known methods for directed mutagenesis. For this purpose, circular single-stranded DNA is produced from suitable vectors (phagemids), e.g. from pCLMUTN1 of Fig. 4 or pCLMUTC1 of Fig. 5, optionally with the assistance of a helper phage, which single-stranded DNA contains the whole of the DNA sequence encoding the protease or, preferably, only the DNA sequence in which the mutation is to be undertaken. A hybridizable synthetic oligonucleotide, which contains, at the desired point mutation site, a nucleotide structural unit which is selected such that the associated codon encodes one of the amino acids already indicated for the relevant position, e.g. arginine in position 114, is hybridized with this circular single stranded D~A. In ~ addition, the oligonucleotide is also altered, as compared - with the original nucleotide sequence which is to be hybridized, by one or a few further nucleotide structural units, such that, while the coding of the original amino acid sequence is preserved within the limits of the degeneracy of the genetic code, either a restriction site ; which may be present in the original nucleotide sequence is removed in the synthetic oligonucleotide, or else a further restriction site is introduced into the synthetic oligonucleotide. The removed or introduced restriction site is later used for distinguishing the mutated DNA sequencç
21~6~
from the starting-type DNA sequence usin~g appropriate restriction endonucleases. In a variant, uracylated single-stranded DNA is produced as the template in the process of directed mutagenesis and used for hybridization to the synthetic oligonucleotides. Once the reactions of the process of directed mutagenesis are complete, the uracil-containing DNA single strand, which served as the template for producing mutated DNA strands (vectors), can be removed by treatment with uracil N-glycosylase without any phenotypic selection of mùtants being required. The glycosylase treatment can be carried out either using the isolated en2yme or else with the aid of a suitable microorganism possessing uracil N-glycosylase activity and transformed with mutated vector DNA.
The completion of the partially double-stranded DNA
sequence obtained by hybridization to give the complete double strand is then carried out by adding the necessary nucleotides and using DNA polymerase and DNA ligase. The circular, double-stranded DNA sequence which is produced is subsequently transformed as a vector into a suitable microorganism. Subsequently, the mutated DNA sequences are identified by means of the unique restriction endonuclease recognition sites and isolated from the transformant. If uracylated single-stranded DNA is employed, the replication 25 is then undertaken in, for example, an E. coli strain which -~
preferentially replicates the mutated, non-uracylated DNA
strand of the double-stranded vector produced in the mutation process. This additionally facilitates selection of the mutated DNA vectors.
~30 The synthetic oligonucleotides which are required for ~` -the directed mutagenesis are prepared by known methods (e.g.
according to Beaucage S.L. and Caruthers M.H., 1981, Tetrahedron Letters 22: 1859-1862).
The circular, double-stranded DNA sequences which were obtained by the directed mutagenesis and which possess the introduced mutations represent mutated vectors from which, - 14 - ~
,: ,.'' ~ : ' :::
depending on the circumstances, the whole mutated protease structural gene or the mutated stretch of the protease structural gene can be excised by treating with appropriate restriction endonucleases and introduced ~subcloned~ into an appropriate expression vector. This expression vector is then used to transform appropriate microorganisms, e.g.
Bacil7us species, which are subsequently cultivated under suitable conditions for expressing and isolating the mutated highly alkaline proteases.
In a preferred embodiment of the invention, the whole structural gene is not employed for the directed mutagenesis, but rather only a stretch thereof in which the mutation is to be produced. For this purpose, the N-terminal or C-terminal half of the structural gene, for example, is excised, using appropriate restriction endonucleases, from the vector which is being used to replicate the structural genes and then subcloned into a suitable phagemid. In this way, vectors are obtained which either contain the N-terminal or the C-terminal half of the structural gene and which are first replicated adequately in a suitable microorganismj for example E. coli, and then ;~ ~ subjected to the aforedescribed directed mutagenesis. An advantage of the mutagenesis of stretches of the DNA of the structural gene is that shorter single-stranded DNA
sequences can be used and thus, following the step of hybridization to synthetic oligonucleotides, appreciably fewer nucleotides have to be added to the partial D~A double strand than is the case when using the entire DNA sequence.
This reduces the synthetic requirements and also the danger ,of undesired accidental mutations.
The mutated DNA sequences can be excised from the vector used for producing the mutations with the aid of appropriate restriction endonucleases and then incorporated into vectors possessing corresponding restriction sites, which vectors represent precursors of the actual expression vectors which are required for expressing the highly .
211~
alkaline protease. These vectors are constructed such that, in addition to the appropriate restriction sites (e.g.
consisting of a synthetic linker), they also already contain the regulatory sequences, signal sequences, promoter sequences, and the DNA sequences encoding the pre- and pro-units of the protease, which are required for expressing the protease in a host organism.
Subcloning a mutated DNA sequence into such a vector produces the actual expression vector for an optimized highly alkaline protease. The mutated DNA sequence is incorporated into this expression vector precursor in such a way that an expression vector which has an appropriate reading frame is obtained. Mutated stretches of the DNA
sequence encoding the protease, e.g. a C-terminal or a N-terminal stretch, can be incorporated into vectors which already contain the relevant remaining non-mutated, or, optionally, also mutated (production of multiple mutations) stretch; alternatively, the whole mutated DNA sequence encoding the protease can be incorporated into vectors which, prior to this, do not contain any stretches of this protease DNA sequence. Examples of such precursor vectors of an expression vector which already contain stretches of the protease gene are the vectors having the designations ; pALlN and pALlC, whose restriction maps are reproduced in 2S Fig. 9 and Fig. 10, respectively.
The expression vector precursors for the preferred variant of the invention (mutation in the N-terminal half or in the C-terminal half) can be obtained, for example, by restricting a Bacillus plasmid at an appropriate site and recombining it with a fragment of an E. coli plasmid which contains a marker and sequence parts which are important for replication. Subsequently, where appropriate, those restriction sites which would interfere with the later procedural steps are removed, for example by directed mutagenesis. A new vector is constructed from the resulting plasmid, which vector contains the DNA sequences from the ..
2~ 1 ~4 ~
Bacillus plasmid and the E. coli plasmid which are used for replication, DNA sequences for the promoter, DNA sequences which encode the pre-pro sequence of the protease (obtained, for example, from the plasmid pCLEAN4 of Fig. 2) and a synthetic linker. The restriction map of Fig. 7 represents an example of such a plasmid having the designation pALlP.
In this regard, the synthetic linker is selected such that, following cleavage with appropriate restriction endonucleases, the vector can be combined with the whole original or mutated DNA sequence encoding the mature protease, or with mutated or non-mutated stretches of the structural gene. In order to prepare an expression vector precursor, which, for example, is to be recombined with a mutated N-terminal half of the structural gene, the non-mutated, or optionally already mutated, C-terminal half of the structural gene, for example, is initially inserted, by means of cleaving the synthetic linker, into the vector which is constructed as above and which contains the said Bacillus and E. coli sequences, the promoter and the pre and pro sequences of the protease, as well as the synthetic linker. Subsequently, the mutated N-terminal half of the structural gene of the protease, which is still lacking, is inserted by means of cleaving the synthetic linker once again. In this way, a vector of the type pALlNC of Fig. 8 is obtained. The procedure for the reverse case is analogous.
In this case, the non-mutated, or optionally already mutated, N-terminal half is initially inserted into a vector and the mutated C-terminal half is incorporated at a later stage into the resulting vector, a vector of the t~pe pALlNC
of Fig. 8 likewise being obtained.
Appropriate bacteria, preferably Bacillus species, in particular Bacillus subtilis, B. licheniformis or B.
alcalophilus, are transformed with the above-described expression vectors. The transformants are subsequently cultured in a known manner and the highly alkaline protease 211~fi~
' .
which is formed is isolated from the culture medium. For this purpose, the expression vectors can be transformed either into bacteria which are still capable of forming indigenous protease, or else into protease-deficient bacteria ~which no longer form indigenous protease). In the case of host organisms which form indigenous protease, the highly alkaline protease accordins to the invention can, if desired, be freed from the indigenous proteases which have formed by subsequent purification operations, for example by high resolution liquid chromatography (HPLC). By contrast, such a purification step can be omitted in the case of protease-deficient host organisms, since these organisms are only ~or essentially only) capable of forming the protease according to the invention.
The following examples are intended to illustrate the invention in further detail without, however, limiting its scope.
Unless otherwise indicated, the methods described in Maniatis et al. (Maniatis et al. = T. Maniatis, E.F.
Fritsch, J. Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, 1982) were generally employed.
Starting vectors used here are available commercially and on an unrestricted basis; otherwise, they can be ~; ~ 25 prepared, by known methods from available vectors.
The Bacillus alcalophilus strain employed in Example 1, and designated Bacillus alcalophilus HAl, was deposited on 28 July 1989 with the Deutsche Sammlung von Mikroorganismen (DSM) ~German Collection of Microorganisms) Braunschweig, Germany under the DSM number 5466.
- , :
~. .
' "~.:;
,: .
2~15~5 . .
Example 1: Preparation of a genomic DNA library from B.
alcalophilus and isolation of the gene for the highly alkaline starting protease.
Chromosomal DNA was isolated from the natural isolate 5 Bacillus alcalophilus HA1 (deposited with the German Collection of Microorganisms under the DSM number 5466) in accordance with the method of Saito et al. ~1963, Biochim.
Biophys. Acta. 72: 619-629) and then partially hydrolysed using the restriction endonuclease Sau3A. The restriction . ~.
~ '' .,,''-', :':
`
. .:
~ :
~ '~
.. .
~ , ,.
:
.:
2 ~
fragments were fractionated by electrophoresis on an agarose gel, and the fragments having a size of from 3 to 8 kilobases (KB) were isolated.
The isolated and size-selected DNA fragments from Bacillus alcalophilus HAl were recombined in vitro with plasmid pUB 110 vector DNA (obtained as described in Example 7).
For this purpose, the plasmid pUB110 was first restricted with the restriction endonuclease BamHI and then dephosphorylated using calf intestinal alkaline phosphatase.
Subsequently, 2 ~g of the restricted and dephosphorylated vector DNA were incubated at 16C for 24 hours together with 8 ~g of the Racillus alcalophilus DNA fragments in a total volume of 100 ~l and in the presence of T4 DNA ligase.
Protoplasts of the strain Baci71us subtilis BD224 were transformed with the resulting DNA, which had been recombined in vitro, in accordance with the method described by S. Chang and N. Cohen (1979, Mol. Gen. Genet. 168~
115). The transformants were selected on plates ; 20 containing neomycin and subsequently transferred to skimmed milk agar. Among 13,800 transformants which were examined, one was found which formed a distinctly larger aureole from proteolysis of the skimmed milk. The plasmid DNA was isolated from this clone in accordance with Maniatis et al. ~ ~ 25 The cloned fragment of B. alcalophilus DNA contained in this plasmid had a size of 4.1 KB and contained the entire information for the highly alkaline protease from Bacillus alcalophilus HAl.
In order to simplify the subsequent procedure, the 4.1 KB-sized DNA fragment was first reduced in size. To do l l , '' ' ' this, the recognition sites for restriction endonucleases located on the DNA fragment were identified by cleaving the plasmid with various restriction endonucleases and:~
fractionating the fragments of the restricted DNA by ~ `
electrophoresis on an agarose gel. A 2.3 KB-sized DNA
fragment, obtained by cleaving with the restriction ~: :
- 20 - ~
. . . ~ . , ' .
2~.:.5~
' !
endonucleases AvaI and HindIII, was identified which contained the complete information for the highly alkaline protease and which was used for the subsequent procedure.
For this, the above plasmid containing the 4.1 KB fragment was restricted with the restriction endonucleases AvaI and HindIII. The 2.3 KB-sized DNA fragment was isolated and ligated to the vector pUB131 (obtained as described in Example 7), which vector had likewise previously been cut with AvaI and HindIII.
The resulting plasmid, which was given the designation pCLEAN4, was introduced into the strain B. subtilis BD224.
The transformants were able to secrete the highly alkaline protease, indicating that the AvaI/HindIII fragment contains the complete structural gene for the highly alkaline protease from B. alcalophilus HA1. The restriction map of the plasmid pCLEAN4 is given in Fig. 2.
Example 2: Sequencing of the structural gene for the highly alkaline protease.
In order to prepare single-stranded DNA of the structural gene of the protease, the plasmid pCLEAN4 was cleaved with the restriction endonucleases AvaI and HindIII
and the approximately 2.3 KB-sized AvaI/HindIII DNA fragment (st~uctural gene of the protease) was introduced into the phagemids pBS (+) or pBS (-). The nucleotide sequence of the protease gene contained in the isolated single-stranded phagemids was determined by the dideoxy chain termination method of Sanger et al. (1977, Proc. Natl. Acad. Sci. USA
74: 5463) and by the method of base-speclfic chemical cleavage of the DNA single strand in accordance with Maxam et al. (1980, in Methods in Enzymology, Grossmann L., Moldave K., eds., Academic Press Inc., New York and London, Vol. 65, 499). The nucleotide sequence which was determined, and the deduced amino acid sequence of the protease, are yiven in Fig. 1. The start of the amino acid sequence of the mature highly alkaline protease, in position 211~65 1190 of the nucleotide sequence, wa~ determined by amino~
acid sequencing the N-terminal end of the highly alkaline protease.
5 Exam~le 3: Preparation of mutated DNA sequences by directed ~
mutagenesis. ~-The directed mutations were carried out in constituent DNA sequences of the structural gene of the protease using ~-the "primer extension" technique described by Kunkel, T.A.
(1985, Proc. Natl. Acad. Sci. USA 82: 488-492). For this purpose, the plasmids pCLMUTN1 (preparation as described in example 4) and pCLMUTC1 (preparation as descr.ibed in Example 5) were employed, being initially converted, as described below, into their uracylated, single-stranded analogs. The starting vectors pCLMUTN1 and pCLMUTC1 do not contain the entire DN~ sequence of the structural gene of the protease from B. alcalophilus HAl, but only the N-terminal half (pCLMUTNl) or the C-terminal half (pCLMUTC1) ther~of.
As descendants of a phagemid, these vectors are ; 20 capable, to a certain extent, of forming single-stranded ; `
vector DNA, which it was possible, under the conditions given here, to transfer out of the host organism being used for replication and then isolate.
Each of these vectors was introduced into E. coli CJ236, as the host organism, using the CaCl2 method, in accordance with Maniatis et al. (pp. 250-251).
Since, when vectors are being replicated, the bacterium E. coli CJ236 (uracil N-glycosylase deficient mutant) incorporates the nucleotide uracil instead of thymine into the DNA sequence of the vector, the uracil-containing analogs of the vectors pCLMUTN1 or pCLMUTC1 were obtained by cultivating the above transformants. These uracil-containing vectors cannot be distinguished from the normal thymine-containing vectors in in vitro reactions. The uracil content of the vector DNA does not interfere with in vi tro DNA syntheses since uracil is not mutagenic either in 211~
vi tro or in vivo, and uracil codes in the same way as thymine. Uracylated vectors can be advantageously employed for the subsequent in vitro reactions of the directed mutagenesis. Once the reactions are complete, the uracil-containing DNA single strand, which served as the templatefor producing mutated DNA strands (vectors), can be removed by treating with uracil N-glycosylase without any phenotypic selection of mutants being required. The glycosylase treatment can be carried out either using the isolated enzyme or else using an E. coli strain possessing uracil N-glycosylase activity which has been transformed with vector DNA.
The uracylated single-stranded DNA of the vectors pCLMUTNl and pCLMUTCl, required as template for the directed mutagenesis, was prepared by cultivating E. coli CJ236 bacteria which had been transformed with one of the two vectors, which bacteria had additionally been infected with ;~ the helper phage M13K07 ~obtained from Bio-Rad Laboratories, Richmond, California).
The helper phage itself is scarcely capable of replication and does not exhibit any interfering interaction ; with the vector DNA of the vectors pCLMUTNl or pCLMUTCl.
Its task consists of synthesizing coat proteins for the uracylated, single-stranded vector DNA which is formed.
Coated single-stranded vector DNA is transferred out of the ~; host organism E. coli CJ236 and can be isolated from the culture medium. The qualitative and quantitative yield of (here of uracylated) single-stranded vector DNA is appreciably increased by the cooperation of the helper phage.
1~ ' ' ' j , .
The isolated, uracylated DNA single-strand vectors pCLMUTNIl or pCLMUTCl were hybridized to the synthetic oligonucleotides, prepared in accordance with Example 8, which containecl a mutation site and simultaneously acted as primers for subsequently completing the DNA double strand possessing a mutation.
21~S~
~:
The synthesis of the second DNA strand was carried out in the presence of nucleotides using T4 DNA polymerase, and the subsequent ligation of the newly formed strand was carried out using T4 DNA ligase (Kunkel et al., 1987, Methods in Enzymol. 154, 367-382). The double-stranded vector DNA which was formed was transformed into E. col i MC1061 and the mutated vectors ~ere identified by testing for the corresponding unique restriction endonuclease recognition sites which had either been introduced or removed by the synthetic oligonucleotides.
In order to prepare, for example, two mutations in either the N-terminal or the C-terminal part of the structural gene of the protease, the procedure of this example was repeated, following the introduction of a first mutation (use of a first synthetic oligonucleotide of Example 6) into one part of the structural gene of the protease, in an analogous manner using a further synthetic oligonucleotide of Example 8 for introducing a second mutation into this part of the structural gene of the protease. In this way, mutated vectors of the type pCLMUTN1 or pCLMUTC1 were obtained which possessed, for example, two mutations in either the N-terminal or the C-terminal part of the structural gene of the protease.
Example 4: Construction of the vector pCLMUTN1.
~` The plasmid pCLEAN4, prepared in Example 1, was cleaved using AvaI. The protruding ends ("sticky ends") were filled in to produce double-stranded DNA using the Klenow fragment of B. col i DNA polymerase I (Maniatis et al., p. 114) in the presence of the necessary nucleotides. After subsequent restriction of this DNA with XbaI, the N-terminal fragment of the protease gene, encompassing 1618 base pairs (BP), was isolated and cloned into the SmaI/XbaI site of pBS. The resulting vector was given the designation pCLMUTN1. The restriction map of this vector is given in Fig. 4.
. :
.
~ .' ' .: ' ` 21~4g~
Example 5: Construction of the vector pCLMUTCl. ;
The plasmid pCLEAN4, prepared in Example 1, was cleaved with the restriction endonucleases XbaI and Asp718. The XbaI/Asp718 double-stranded DNA fragment, encompassing 658 BP and containing the C-terminal half of the structural gene of the protease, was cloned into the XbaI/Asp718 site of pBS. The resulting vector was given the designation pCLMUTCl. The restriction map of the vector is given in Fig. 5. -~
1 0 ~ , Example 6: Synthesis of artificial oligonucleotides for the directed mutagenesis.
Synthetic oligonucleotides were prepared in a Cyclone ~-~
synthesizer (Biosearch) by the method of Beaucage S.L. and Caruthers M.H. (1981, Tetrahedron Letters 22: 1859-1862) using ~-cyanoethyl phosphoramidite. The resulting oligonucleotides were purified by elution from polyacrylamide gels and subsequent desalting using Sephadex G25 columns. Examples of the synthesized nucleotide -sequences (SEQUENCE ID NOS:2-6), and of their properties, ; are given in Fig. 3. The sequences of the synthetic oligonucleotides, used in the procedure according to Example ~; 3 for introducing the mutations into the protease gene, were selected such that they fulfilled the following conditions.
- The DNA sequence of the synthetic oligonucleotide was still sufficiently complementary to the corresponding sequence of the protease gene to ensure that its ability to hybridize was adequate.
Replacement of one or more nucleotides within the I codon, encoding the amino acid to be replaced, by other nucleotides such that this mutated codon now encoded a different amino acid (mutation). That codon was employed for the new amino acid which most frequently ; occurred for the corresponding amino acid in the protease gene.
c 211S~6a ' .
- Replacement of further nucleotides within other codons such that, while the original coding of the amino acid was preserved, recognition sequences for restriction endonucleases were thereby either removed from the protease gene or else newly produced in it. These recognition sites were used in the proceduxe according to Example 3 for facilitating screening for the vectors possessing the mutated DN~ sequences for the novel highly alkaline proteases.
,.. ....
Example 7: Isolation and purification of the plasmid pUBllO
and construction of the vector pUB131.
The plasmid pUBllO was isolated from the strain ~: Bacillus subtilis BD366 by the method of T.J. Gryczan et al.
(1978, J. Bacteriol. 134: 318-329) and subsequently purified by cesium chloride density gradient centrifugation in accordance with Maniatis et al. (p. 93). The vector pUBllO
contains uniquely occurring restriction sites for the restriction endonucleases BamHI and EcoRI, a DNA sequence, as a marker, which encodes antibiotic resistance to neomycin, and DNA sequences ("origin of replication") which are required for replication in Bacillus species.
The plasmid pUBllO which was obtained above was restricted with EcoRI and BamHI. The smaller fragment (790 BP) was replaced by a polylinker consisting of 67 base `~
pairs, which polylinker had previously been isolated as an EcoRI/BglII f~agment from the vector M13tgl31. The resulting vector, having the designation pUB131, is thus a descendant of pUBllO in which the approximately 0.8 KB-sized EcoRI/BamHI fragment has been deleted and replaced by a polycloning site.
; Example 8: Construction of the vectors pUBC131 and pUBC132.
The plasmid pUC18 was cleaved with AatII and PvuII. -35 The 1990 base pair-sized fragment containing the ~-lactamase ~ -gene and the E. coli "origin of replication" was isolated.
- 26 - ~ ~
, ' , ' "
2 1 ~
The protruding ends ("sticky ends") were filled in to produce double-stranded DNA using the Klenow fragment of E.
coli DNA polymerase I (Maniatis et al., p. 114) in the presence of the necessary nucleotides. The fragment was subsequently incorporated into the SnaBI site of the vector pUB131, obtained in accordance with Example 7, resulting in the production of the vector given the designation pUBC131.
The 2187 BP EcoRI/BglII fragment of the vector pUBC131, which was obtained above, was subcloned into the EcoRI/BamHI
site of pBS (+), resulting in the production of the vector given the designation pBSREPU. Subsequently, the NcoI or StyI recognition site, which is present in the DNA sequence for the repU polypeptide in the vector pBSREPU (I. Maciag et al. 1988, Mol. Gen. Genet. 212: 232-240), was eliminated by directed mutagenesis in that the nucleotide sequence CCA TGG
was replaced by the nucleotide sequence CCG TGG (both nucleotide sequences encode the amino acid sequence trypto-phan-proline). This was carried out analogously to the procedure used in Example 3. For this purpose, uracylated single-stranded DNA (SEQUENCE ID NO:7) of the vector pBSREPU
was prepared as the template for the directed mutation for eliminating the NcoI or StyI recognition site.
Subsequently, this template was converted, in analogy with the "primer extension" technique described in Example 3, into the completely double-stranded DNA vector using the following synthetic oligonucleotide (SEQUENCE ID NO:8) (prepared and purified in analogously to the process used to prepare the synthetic oligonucleotides of Example 6) NcoI/StyI
Pro Trp Original repU sequence : A~A GTG AGA CCA TGG AGA GAA AA
Synthetic repU sequence: AAA GTG AGA CCg TGG AGA GAA AA
and the vectors, which were now free of NcoI or StyI
recognition sites, were isolated by transforming and cultivating E. coli MC1061. The 1726 BP EcoRI/ApaI fragment of the isolated vector was inserted into the EcoRI/ApaI site of pUBC131. The new vector, whose restriction map is given in Fig. 6, received the designation pUBC132.
5 Example 9: Construction of the plasmid pALlP. ~;
The plasmid pALlP was prepared by ligating the following three elements:
- The 1201 base pair-sized AvaI/NcoI fragment of pCLEAN4;
the fragment contains the promoter and the pre-pro region of the highly alkaline starting protease.
- The following synthetic linker (SEQUENCE ID NOS:9-10) containing individual recognition sites for the restriction endonucleases NcoI, XbaI and Asp718 which permit the introduction of the mutated N-terminal or C-terminal halves of the protease gene from the mutated vectors pCLMUTN1 and pCLMUTC1, respectively, or the introduction of the whole gene of the starting protease ~ from the plasmid pCLEAN4; :
;~ 5' - CCATGGTCTAGAGGTACCA - 3' ~ 20 3' - CAGATCTCCATGGTTCGA~ - 5' ~ ~ A
NcoI XbaI Asp718 HindII
The above double-stranded synthetic linker with protruding 5' ends was prepared by first separately producing the two single-stranded DNA sequences (SEQUENCE ID NOS:9-10) analogously to the synthesis of the synthetic oligonucleotides in Example 6 and then purifying them. The resulting single strands were subsequently hybridized to each other to form the double strand.
- The 5776 base pair-sized AvaI/HindIII fragment from the vector pUBC132 prepared in Example 8; this fragment contains DN~ sequences for replication and for use as selectable markers in E. coli as well as DNA sequences . . :
for replication and for use as selectable markers in B.
subtilis, B. licheniformis and B. alcalophilus. ~ :
The construction of the vector pALlP was carried out in E. coli MC1061 and the vector was isolated from ampicillin-resistant E. coli transformants. The restriction map of theresulting vector is given in Fig. 7.
Example 10: Construction of the plasmids pALlN and pALlC.
The vectors pALlN and pALlC were constructed in E. coli MC1061, the vectors being isolated from ampicillin-resistant E. coli transformants.
The plasmid pALlN was constructed by initially cleaving the vector pCLEAN4 obtained in Example 1 with the restriction endonucleases NcoI and XbaI and subsequently cloning the resulting NcoI/XbaI fragment into the NcoI/XbaI
site of the vector pALlP (prepared in accordance with Example 9). The vector which was prepared contained the N-terminal part of the DNA sequence encoding the mature enzyme, the regulatory elements for transcribing and translating the highly alkaline protease, as well as the signal and processing sequences.
The plasmid pALlC was constructed by first cleaving the vector pCLEAN4, obtained in Example 1, with the restriction endonucleases XbaI and Asp718 and then cloning the resulting 2S XbaI/Asp718 fragment into the XbaI/Asp718 site of the vector pALlP (prepared in accordance with Example 9). The vector which was prepared contained the C-terminal part of the DNA
sequence encoding the mature protease, the regulatory elements for transcribing and translating the highly ;~ 30 alkaline protease, as well as the signal and processing sequences.
Example 11: Construction of the expression vectors pALlNC.
Expression vectors were prepared having mutations in the C-terminal part of the protease DN~ sequence, as were those having mutations in the N-terminal part of the , : , 2 1 1 ~
protease DNA sequence, those having mutations in the N-terminal and C-terminal parts of the DNA sequence, and, for comparative purposes, also those without mutations in the protease DNA sequence.
A. Expression vector having mutations in the N-terminal part of the D~A sequence of the protease The mutated vector pCLMUTN1, which was obtained by directed mutagenesis in accordance with Example 3, was cleaved with the restriction endonucleases NcoI and XbaI.
The isolated 411 base pair-sized NcoI/~baI fragment (mutated N-terminal part of the structural gene of the protease having, respectively, the mutations N42R, N114R, I43Q, N42R/N114R and I43Q/N114R, N42R/I43Q, N42R/I43Q/N114R) was cloned into the NcoI/XbaI site of the plasmid pALlC obtained in accordance with Example 15. The vector obtained in each ~ case represents a complete expression vector having a ; ~ suitable reading frame for expressing a mutated protease.
The vectors were designated as follows~
20 pALN42R = expression vector for the protease having the mutation N42R;
pALI43Q = expression vector for the protease having the mutation I43Q;
pALN114R = expression vector for the protease having ; 25 the mutation N114R;
pALN42R/N114R = expression vector for the protease having the mutations N42R/N114R;
pALI43Q/N114R = expression vector for the protease having -the mutations I43Q/N114R.
pALN42R/I43Q = expression vector for the protease having the mutations N42R/I43Q.
pALN42R/I43Q/
N114R = expression vector for the protease having ;
the mutations N42R/I43Q/N114R.
~ ' ' :''~ ,' 21~5~
, B. Expression vector having mutations in the C-terminal part of the DNA sequence of the protèase The mutated vector pCLMUTCl, which was obtained by directed mutagenesis in accordance with Example 3, was cleaved with the restriction endonucleases XbaI and Asp718.
The isolated 609 base pair-sized XbaI/Asp718 fragment (mutated C-terminal part of the structural gene of the protease having, respectively, the mutations M216Q, T249E
and M216Q/T249E) was cloned into the XbaI/Asp718 site of the plasmid pALlN obtained in accordance with Example 10. The vector obtained in each case represents a complete expression vector having a suitable reading frame for expressing a mutated protease. The vectors were designated as follows:
15 pALM216Q = expression vector for the protease having the mutation M216Q;
pALT249E = expression vector for the protease having the mutations T249E;
pALM216Q/T249E = expression vector for the protease having .
the mutations M216Q/T249E.
C. Expression vector having mutations in the C-terminal and N-terminal part of the protease DNA sequence The expression vector pALN114R, prepared in this example under A., and the expression vector pALM216Q, prepared under B., were in each case cleaved with the restriction endonucleases XbaI and AvaI. The 1612 base pair-sized fragment of the plasmid pALN114R was ligated to the 6388 base pair-sized fragment of the plasmid pALM216Q.
The resulting plasmid was given the designation ,, , , j , , pALN114R/M216Q.
The following expression vectors were prepared in an analogous manner:
pALN114R!M216Q
35 pALI43Q/M216Q
pALN42R/M216Q
. .
2 ~ 6 ~ .~
.:
.
pALI43Q/M216Q/T249E ~`
pALI43Q/N114R/T249E
pALI43Q/N114R/M216Q/T249E
- pALN42R/I43Q/N114R/M216Q/T249E
pALN114R/T249E
pALI43Q/N114R/M216Q
pALN114R/M216S
pALI43Q/M216S/T249E
pALN42R/M216A
pALN42R/M216A/T249E. ~ -D. Expression vector containing the non-mutated DNA
sequence of the starting protease The expression vector containing the non-mutated ~-starting structural gene of the protease was obtained by either cloning the 411 base pair-sized, non-mutated NcoI/XbaI fragment from the plasmid PCLEAN4, obtained in accordance with Example 1, into the NcoI/XbaI site of the -`
~; plasmid pALlC, obtained in accordance with Example 10; or by ~-cloning the 609 base pair-sized XbaI/Asp718 fragment from the plasmid pCLEAN4, obtained in accordance with Example 1, into the XbaI/Asp718 site of the plasmid pALlN, obtained in accordance with Example 10. The vectors thus obtained are complete expression vectors having a suitable reading frame for expressing the non-mutated highly alkaline starting protease.
The restriction map of these vectors of the type pALlNC ~ --; is given in Fig. 8.
Exam~le 12: Preparation of the highly alkaline proteases which have been altered by mutation and, for comparative ;~;
purposes, of the starting protease.
50 ml of preculture medium (20 g of tryptone, 10 g of ` yeast extract, 5 g of NaCl, 75 g of soluble starch and 10 ml of corn steep liquor per liter) were in each case inoculated with a colony of the strains to be tested (in each case B. ~ ~
- 32 - ~ `
. , ` ' :, 21~6~
, subtilis BD224 transformed with one of the pALlNC vectors prepared in accordance with Example 11). The culture was incubated at 37C for 16 hours and at 250 rpm. 50 ml of main culture medium (30 g of soya bean meal, 90 g of potato starch, 10 g of Na caseinate and 10 ml of corn steep liquor per liter) were inoculated with 2.5 ml of this culture. The main culture was incubated uncler conditions which were identical to those used for the preculture. After 72 hours, the cultures were centrifuged. The proteases which had been formed were precipitated from the culture supernatants using acetone and subsequently purified as follows: cation exchanger Mono S, FPLC; elution using an ascending gradient of 20 mmole to 200 mmole ammonium acetate, pH = 6.
The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed to include everything within the scope of the appended claims and equivalents thereof.
~, :'' ' - 33 - :: :
. ' ,~: .... . ~ '
mutagenesis. ~-The directed mutations were carried out in constituent DNA sequences of the structural gene of the protease using ~-the "primer extension" technique described by Kunkel, T.A.
(1985, Proc. Natl. Acad. Sci. USA 82: 488-492). For this purpose, the plasmids pCLMUTN1 (preparation as described in example 4) and pCLMUTC1 (preparation as descr.ibed in Example 5) were employed, being initially converted, as described below, into their uracylated, single-stranded analogs. The starting vectors pCLMUTN1 and pCLMUTC1 do not contain the entire DN~ sequence of the structural gene of the protease from B. alcalophilus HAl, but only the N-terminal half (pCLMUTNl) or the C-terminal half (pCLMUTC1) ther~of.
As descendants of a phagemid, these vectors are ; 20 capable, to a certain extent, of forming single-stranded ; `
vector DNA, which it was possible, under the conditions given here, to transfer out of the host organism being used for replication and then isolate.
Each of these vectors was introduced into E. coli CJ236, as the host organism, using the CaCl2 method, in accordance with Maniatis et al. (pp. 250-251).
Since, when vectors are being replicated, the bacterium E. coli CJ236 (uracil N-glycosylase deficient mutant) incorporates the nucleotide uracil instead of thymine into the DNA sequence of the vector, the uracil-containing analogs of the vectors pCLMUTN1 or pCLMUTC1 were obtained by cultivating the above transformants. These uracil-containing vectors cannot be distinguished from the normal thymine-containing vectors in in vitro reactions. The uracil content of the vector DNA does not interfere with in vi tro DNA syntheses since uracil is not mutagenic either in 211~
vi tro or in vivo, and uracil codes in the same way as thymine. Uracylated vectors can be advantageously employed for the subsequent in vitro reactions of the directed mutagenesis. Once the reactions are complete, the uracil-containing DNA single strand, which served as the templatefor producing mutated DNA strands (vectors), can be removed by treating with uracil N-glycosylase without any phenotypic selection of mutants being required. The glycosylase treatment can be carried out either using the isolated enzyme or else using an E. coli strain possessing uracil N-glycosylase activity which has been transformed with vector DNA.
The uracylated single-stranded DNA of the vectors pCLMUTNl and pCLMUTCl, required as template for the directed mutagenesis, was prepared by cultivating E. coli CJ236 bacteria which had been transformed with one of the two vectors, which bacteria had additionally been infected with ;~ the helper phage M13K07 ~obtained from Bio-Rad Laboratories, Richmond, California).
The helper phage itself is scarcely capable of replication and does not exhibit any interfering interaction ; with the vector DNA of the vectors pCLMUTNl or pCLMUTCl.
Its task consists of synthesizing coat proteins for the uracylated, single-stranded vector DNA which is formed.
Coated single-stranded vector DNA is transferred out of the ~; host organism E. coli CJ236 and can be isolated from the culture medium. The qualitative and quantitative yield of (here of uracylated) single-stranded vector DNA is appreciably increased by the cooperation of the helper phage.
1~ ' ' ' j , .
The isolated, uracylated DNA single-strand vectors pCLMUTNIl or pCLMUTCl were hybridized to the synthetic oligonucleotides, prepared in accordance with Example 8, which containecl a mutation site and simultaneously acted as primers for subsequently completing the DNA double strand possessing a mutation.
21~S~
~:
The synthesis of the second DNA strand was carried out in the presence of nucleotides using T4 DNA polymerase, and the subsequent ligation of the newly formed strand was carried out using T4 DNA ligase (Kunkel et al., 1987, Methods in Enzymol. 154, 367-382). The double-stranded vector DNA which was formed was transformed into E. col i MC1061 and the mutated vectors ~ere identified by testing for the corresponding unique restriction endonuclease recognition sites which had either been introduced or removed by the synthetic oligonucleotides.
In order to prepare, for example, two mutations in either the N-terminal or the C-terminal part of the structural gene of the protease, the procedure of this example was repeated, following the introduction of a first mutation (use of a first synthetic oligonucleotide of Example 6) into one part of the structural gene of the protease, in an analogous manner using a further synthetic oligonucleotide of Example 8 for introducing a second mutation into this part of the structural gene of the protease. In this way, mutated vectors of the type pCLMUTN1 or pCLMUTC1 were obtained which possessed, for example, two mutations in either the N-terminal or the C-terminal part of the structural gene of the protease.
Example 4: Construction of the vector pCLMUTN1.
~` The plasmid pCLEAN4, prepared in Example 1, was cleaved using AvaI. The protruding ends ("sticky ends") were filled in to produce double-stranded DNA using the Klenow fragment of B. col i DNA polymerase I (Maniatis et al., p. 114) in the presence of the necessary nucleotides. After subsequent restriction of this DNA with XbaI, the N-terminal fragment of the protease gene, encompassing 1618 base pairs (BP), was isolated and cloned into the SmaI/XbaI site of pBS. The resulting vector was given the designation pCLMUTN1. The restriction map of this vector is given in Fig. 4.
. :
.
~ .' ' .: ' ` 21~4g~
Example 5: Construction of the vector pCLMUTCl. ;
The plasmid pCLEAN4, prepared in Example 1, was cleaved with the restriction endonucleases XbaI and Asp718. The XbaI/Asp718 double-stranded DNA fragment, encompassing 658 BP and containing the C-terminal half of the structural gene of the protease, was cloned into the XbaI/Asp718 site of pBS. The resulting vector was given the designation pCLMUTCl. The restriction map of the vector is given in Fig. 5. -~
1 0 ~ , Example 6: Synthesis of artificial oligonucleotides for the directed mutagenesis.
Synthetic oligonucleotides were prepared in a Cyclone ~-~
synthesizer (Biosearch) by the method of Beaucage S.L. and Caruthers M.H. (1981, Tetrahedron Letters 22: 1859-1862) using ~-cyanoethyl phosphoramidite. The resulting oligonucleotides were purified by elution from polyacrylamide gels and subsequent desalting using Sephadex G25 columns. Examples of the synthesized nucleotide -sequences (SEQUENCE ID NOS:2-6), and of their properties, ; are given in Fig. 3. The sequences of the synthetic oligonucleotides, used in the procedure according to Example ~; 3 for introducing the mutations into the protease gene, were selected such that they fulfilled the following conditions.
- The DNA sequence of the synthetic oligonucleotide was still sufficiently complementary to the corresponding sequence of the protease gene to ensure that its ability to hybridize was adequate.
Replacement of one or more nucleotides within the I codon, encoding the amino acid to be replaced, by other nucleotides such that this mutated codon now encoded a different amino acid (mutation). That codon was employed for the new amino acid which most frequently ; occurred for the corresponding amino acid in the protease gene.
c 211S~6a ' .
- Replacement of further nucleotides within other codons such that, while the original coding of the amino acid was preserved, recognition sequences for restriction endonucleases were thereby either removed from the protease gene or else newly produced in it. These recognition sites were used in the proceduxe according to Example 3 for facilitating screening for the vectors possessing the mutated DN~ sequences for the novel highly alkaline proteases.
,.. ....
Example 7: Isolation and purification of the plasmid pUBllO
and construction of the vector pUB131.
The plasmid pUBllO was isolated from the strain ~: Bacillus subtilis BD366 by the method of T.J. Gryczan et al.
(1978, J. Bacteriol. 134: 318-329) and subsequently purified by cesium chloride density gradient centrifugation in accordance with Maniatis et al. (p. 93). The vector pUBllO
contains uniquely occurring restriction sites for the restriction endonucleases BamHI and EcoRI, a DNA sequence, as a marker, which encodes antibiotic resistance to neomycin, and DNA sequences ("origin of replication") which are required for replication in Bacillus species.
The plasmid pUBllO which was obtained above was restricted with EcoRI and BamHI. The smaller fragment (790 BP) was replaced by a polylinker consisting of 67 base `~
pairs, which polylinker had previously been isolated as an EcoRI/BglII f~agment from the vector M13tgl31. The resulting vector, having the designation pUB131, is thus a descendant of pUBllO in which the approximately 0.8 KB-sized EcoRI/BamHI fragment has been deleted and replaced by a polycloning site.
; Example 8: Construction of the vectors pUBC131 and pUBC132.
The plasmid pUC18 was cleaved with AatII and PvuII. -35 The 1990 base pair-sized fragment containing the ~-lactamase ~ -gene and the E. coli "origin of replication" was isolated.
- 26 - ~ ~
, ' , ' "
2 1 ~
The protruding ends ("sticky ends") were filled in to produce double-stranded DNA using the Klenow fragment of E.
coli DNA polymerase I (Maniatis et al., p. 114) in the presence of the necessary nucleotides. The fragment was subsequently incorporated into the SnaBI site of the vector pUB131, obtained in accordance with Example 7, resulting in the production of the vector given the designation pUBC131.
The 2187 BP EcoRI/BglII fragment of the vector pUBC131, which was obtained above, was subcloned into the EcoRI/BamHI
site of pBS (+), resulting in the production of the vector given the designation pBSREPU. Subsequently, the NcoI or StyI recognition site, which is present in the DNA sequence for the repU polypeptide in the vector pBSREPU (I. Maciag et al. 1988, Mol. Gen. Genet. 212: 232-240), was eliminated by directed mutagenesis in that the nucleotide sequence CCA TGG
was replaced by the nucleotide sequence CCG TGG (both nucleotide sequences encode the amino acid sequence trypto-phan-proline). This was carried out analogously to the procedure used in Example 3. For this purpose, uracylated single-stranded DNA (SEQUENCE ID NO:7) of the vector pBSREPU
was prepared as the template for the directed mutation for eliminating the NcoI or StyI recognition site.
Subsequently, this template was converted, in analogy with the "primer extension" technique described in Example 3, into the completely double-stranded DNA vector using the following synthetic oligonucleotide (SEQUENCE ID NO:8) (prepared and purified in analogously to the process used to prepare the synthetic oligonucleotides of Example 6) NcoI/StyI
Pro Trp Original repU sequence : A~A GTG AGA CCA TGG AGA GAA AA
Synthetic repU sequence: AAA GTG AGA CCg TGG AGA GAA AA
and the vectors, which were now free of NcoI or StyI
recognition sites, were isolated by transforming and cultivating E. coli MC1061. The 1726 BP EcoRI/ApaI fragment of the isolated vector was inserted into the EcoRI/ApaI site of pUBC131. The new vector, whose restriction map is given in Fig. 6, received the designation pUBC132.
5 Example 9: Construction of the plasmid pALlP. ~;
The plasmid pALlP was prepared by ligating the following three elements:
- The 1201 base pair-sized AvaI/NcoI fragment of pCLEAN4;
the fragment contains the promoter and the pre-pro region of the highly alkaline starting protease.
- The following synthetic linker (SEQUENCE ID NOS:9-10) containing individual recognition sites for the restriction endonucleases NcoI, XbaI and Asp718 which permit the introduction of the mutated N-terminal or C-terminal halves of the protease gene from the mutated vectors pCLMUTN1 and pCLMUTC1, respectively, or the introduction of the whole gene of the starting protease ~ from the plasmid pCLEAN4; :
;~ 5' - CCATGGTCTAGAGGTACCA - 3' ~ 20 3' - CAGATCTCCATGGTTCGA~ - 5' ~ ~ A
NcoI XbaI Asp718 HindII
The above double-stranded synthetic linker with protruding 5' ends was prepared by first separately producing the two single-stranded DNA sequences (SEQUENCE ID NOS:9-10) analogously to the synthesis of the synthetic oligonucleotides in Example 6 and then purifying them. The resulting single strands were subsequently hybridized to each other to form the double strand.
- The 5776 base pair-sized AvaI/HindIII fragment from the vector pUBC132 prepared in Example 8; this fragment contains DN~ sequences for replication and for use as selectable markers in E. coli as well as DNA sequences . . :
for replication and for use as selectable markers in B.
subtilis, B. licheniformis and B. alcalophilus. ~ :
The construction of the vector pALlP was carried out in E. coli MC1061 and the vector was isolated from ampicillin-resistant E. coli transformants. The restriction map of theresulting vector is given in Fig. 7.
Example 10: Construction of the plasmids pALlN and pALlC.
The vectors pALlN and pALlC were constructed in E. coli MC1061, the vectors being isolated from ampicillin-resistant E. coli transformants.
The plasmid pALlN was constructed by initially cleaving the vector pCLEAN4 obtained in Example 1 with the restriction endonucleases NcoI and XbaI and subsequently cloning the resulting NcoI/XbaI fragment into the NcoI/XbaI
site of the vector pALlP (prepared in accordance with Example 9). The vector which was prepared contained the N-terminal part of the DNA sequence encoding the mature enzyme, the regulatory elements for transcribing and translating the highly alkaline protease, as well as the signal and processing sequences.
The plasmid pALlC was constructed by first cleaving the vector pCLEAN4, obtained in Example 1, with the restriction endonucleases XbaI and Asp718 and then cloning the resulting 2S XbaI/Asp718 fragment into the XbaI/Asp718 site of the vector pALlP (prepared in accordance with Example 9). The vector which was prepared contained the C-terminal part of the DNA
sequence encoding the mature protease, the regulatory elements for transcribing and translating the highly ;~ 30 alkaline protease, as well as the signal and processing sequences.
Example 11: Construction of the expression vectors pALlNC.
Expression vectors were prepared having mutations in the C-terminal part of the protease DN~ sequence, as were those having mutations in the N-terminal part of the , : , 2 1 1 ~
protease DNA sequence, those having mutations in the N-terminal and C-terminal parts of the DNA sequence, and, for comparative purposes, also those without mutations in the protease DNA sequence.
A. Expression vector having mutations in the N-terminal part of the D~A sequence of the protease The mutated vector pCLMUTN1, which was obtained by directed mutagenesis in accordance with Example 3, was cleaved with the restriction endonucleases NcoI and XbaI.
The isolated 411 base pair-sized NcoI/~baI fragment (mutated N-terminal part of the structural gene of the protease having, respectively, the mutations N42R, N114R, I43Q, N42R/N114R and I43Q/N114R, N42R/I43Q, N42R/I43Q/N114R) was cloned into the NcoI/XbaI site of the plasmid pALlC obtained in accordance with Example 15. The vector obtained in each ~ case represents a complete expression vector having a ; ~ suitable reading frame for expressing a mutated protease.
The vectors were designated as follows~
20 pALN42R = expression vector for the protease having the mutation N42R;
pALI43Q = expression vector for the protease having the mutation I43Q;
pALN114R = expression vector for the protease having ; 25 the mutation N114R;
pALN42R/N114R = expression vector for the protease having the mutations N42R/N114R;
pALI43Q/N114R = expression vector for the protease having -the mutations I43Q/N114R.
pALN42R/I43Q = expression vector for the protease having the mutations N42R/I43Q.
pALN42R/I43Q/
N114R = expression vector for the protease having ;
the mutations N42R/I43Q/N114R.
~ ' ' :''~ ,' 21~5~
, B. Expression vector having mutations in the C-terminal part of the DNA sequence of the protèase The mutated vector pCLMUTCl, which was obtained by directed mutagenesis in accordance with Example 3, was cleaved with the restriction endonucleases XbaI and Asp718.
The isolated 609 base pair-sized XbaI/Asp718 fragment (mutated C-terminal part of the structural gene of the protease having, respectively, the mutations M216Q, T249E
and M216Q/T249E) was cloned into the XbaI/Asp718 site of the plasmid pALlN obtained in accordance with Example 10. The vector obtained in each case represents a complete expression vector having a suitable reading frame for expressing a mutated protease. The vectors were designated as follows:
15 pALM216Q = expression vector for the protease having the mutation M216Q;
pALT249E = expression vector for the protease having the mutations T249E;
pALM216Q/T249E = expression vector for the protease having .
the mutations M216Q/T249E.
C. Expression vector having mutations in the C-terminal and N-terminal part of the protease DNA sequence The expression vector pALN114R, prepared in this example under A., and the expression vector pALM216Q, prepared under B., were in each case cleaved with the restriction endonucleases XbaI and AvaI. The 1612 base pair-sized fragment of the plasmid pALN114R was ligated to the 6388 base pair-sized fragment of the plasmid pALM216Q.
The resulting plasmid was given the designation ,, , , j , , pALN114R/M216Q.
The following expression vectors were prepared in an analogous manner:
pALN114R!M216Q
35 pALI43Q/M216Q
pALN42R/M216Q
. .
2 ~ 6 ~ .~
.:
.
pALI43Q/M216Q/T249E ~`
pALI43Q/N114R/T249E
pALI43Q/N114R/M216Q/T249E
- pALN42R/I43Q/N114R/M216Q/T249E
pALN114R/T249E
pALI43Q/N114R/M216Q
pALN114R/M216S
pALI43Q/M216S/T249E
pALN42R/M216A
pALN42R/M216A/T249E. ~ -D. Expression vector containing the non-mutated DNA
sequence of the starting protease The expression vector containing the non-mutated ~-starting structural gene of the protease was obtained by either cloning the 411 base pair-sized, non-mutated NcoI/XbaI fragment from the plasmid PCLEAN4, obtained in accordance with Example 1, into the NcoI/XbaI site of the -`
~; plasmid pALlC, obtained in accordance with Example 10; or by ~-cloning the 609 base pair-sized XbaI/Asp718 fragment from the plasmid pCLEAN4, obtained in accordance with Example 1, into the XbaI/Asp718 site of the plasmid pALlN, obtained in accordance with Example 10. The vectors thus obtained are complete expression vectors having a suitable reading frame for expressing the non-mutated highly alkaline starting protease.
The restriction map of these vectors of the type pALlNC ~ --; is given in Fig. 8.
Exam~le 12: Preparation of the highly alkaline proteases which have been altered by mutation and, for comparative ;~;
purposes, of the starting protease.
50 ml of preculture medium (20 g of tryptone, 10 g of ` yeast extract, 5 g of NaCl, 75 g of soluble starch and 10 ml of corn steep liquor per liter) were in each case inoculated with a colony of the strains to be tested (in each case B. ~ ~
- 32 - ~ `
. , ` ' :, 21~6~
, subtilis BD224 transformed with one of the pALlNC vectors prepared in accordance with Example 11). The culture was incubated at 37C for 16 hours and at 250 rpm. 50 ml of main culture medium (30 g of soya bean meal, 90 g of potato starch, 10 g of Na caseinate and 10 ml of corn steep liquor per liter) were inoculated with 2.5 ml of this culture. The main culture was incubated uncler conditions which were identical to those used for the preculture. After 72 hours, the cultures were centrifuged. The proteases which had been formed were precipitated from the culture supernatants using acetone and subsequently purified as follows: cation exchanger Mono S, FPLC; elution using an ascending gradient of 20 mmole to 200 mmole ammonium acetate, pH = 6.
The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed to include everything within the scope of the appended claims and equivalents thereof.
~, :'' ' - 33 - :: :
. ' ,~: .... . ~ '
Claims (19)
1. A highly alkaline protease having an amino acid sequence at least 80% homologous to the amino acid sequence of Fig. 1, and wherein from 2 to 5 of the following substitutions have been effected the amino acid in the position corresponding to position 42 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine, the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by an amino acid selected from the group consisting of serine, glutamine and alanine, and the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid.
2. A highly alkaline protease according to claim 1, wherein said protease has an amino acid sequence at least 90% homologous to the amino acid sequence of Fig. 1.
3. A highly alkaline protease according to claim 2, wherein said protease has an amino acid sequence at least 95% homologous to the amino acid sequence of Fig. 1.
4. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 216 of Fig 1 is replaced by serine, glutamine or alanine, and the amino acid in the position corresponding to position 43 of Fig 1 is replaced by glutamine.
5. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 216 of Fig 1 is replaced by serine, glutamine or alanine, and the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine
6. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine, and the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid.
7. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine; the amino acid located in the position corresponding to position 114 of Fig. 1 is replaced by arginine, and the amino acid in the position corresponding to position 42 of Fig. 1 is replaced by arginine.
8. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine; the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, and the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine.
9. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine; the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid, and the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine.
10. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine; the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid, and the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine.
11. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine; the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine; the amino acid in the position corresponding to position 249 of Fig.
1 is replaced by glutamic acid, and the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine.
1 is replaced by glutamic acid, and the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine.
12. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position-corresponding to position 216 of Fig. 1 is replaced by glutamine.
13. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, and the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine.
14. A highly alkaline protease according to claim 1, having an amino acid sequence in which the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, and the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid.
15. A DNA sequence encoding a highly alkaline protease having an amino acid sequence at least 80% homologous to the amino acid sequence of Fig. 1, and wherein from 2 to 5 of the following replacements have been effected:
the amino acid in the position corresponding to position 42 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine, the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by an amino acid selected from the group consisting of serine, glutamine and alanine, and the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid.
the amino acid in the position corresponding to position 42 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine, the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by an amino acid selected from the group consisting of serine, glutamine and alanine, and the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid.
16. A washing composition comprising a highly alkaline protease according to claim 1, and at least one conventional detergent ingredient.
17. A composition according to claim 16, comprising said highly alkaline protease and at least one further enzyme selected from the group consisting of proteases, lipases, pectinases, amylases, nucleases, oxidoreductases and cellulases.
18. A composition according to claim 16, comprising said highly alkaline protease and at least one further ingredient, selected from the group consisting of surfactants, builders, bleaching agents and bleach activators.
19. A process for preparing a highly alkaline protease comprising the steps of cultivating a transformed microorganism which contains an expressible DNA sequence encoding an amino acid sequence at least 80% homologous to the amino acid sequence of Fig.
1, and wherein from 2 to 5 of the following substitutions have been effected:
the amino acid in the position corresponding to position 42 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine, the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine, and the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid, whereby said highly alkaline protease is produced by said transformed microorganism; and isolating said highly alkaline protease.
1, and wherein from 2 to 5 of the following substitutions have been effected:
the amino acid in the position corresponding to position 42 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 43 of Fig. 1 is replaced by glutamine, the amino acid in the position corresponding to position 114 of Fig. 1 is replaced by arginine, the amino acid in the position corresponding to position 216 of Fig. 1 is replaced by serine, glutamine or alanine, and the amino acid in the position corresponding to position 249 of Fig. 1 is replaced by glutamic acid, whereby said highly alkaline protease is produced by said transformed microorganism; and isolating said highly alkaline protease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19934304161 DE4304161A1 (en) | 1993-02-12 | 1993-02-12 | Improved highly alkaline proteases |
DEP4304161.2 | 1993-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2115465A1 true CA2115465A1 (en) | 1994-08-13 |
Family
ID=6480262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2115465 Abandoned CA2115465A1 (en) | 1993-02-12 | 1994-02-11 | Highly alkaline proteases, dna sequences encoding them and process for their production |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0610808A3 (en) |
JP (1) | JPH06296487A (en) |
BR (1) | BR9400486A (en) |
CA (1) | CA2115465A1 (en) |
DE (1) | DE4304161A1 (en) |
FI (1) | FI940647A (en) |
MX (1) | MX9401068A (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4411223A1 (en) * | 1994-03-31 | 1995-10-05 | Solvay Enzymes Gmbh & Co Kg | Use of alkaline proteases in commercial textile washing processes |
PL366249A1 (en) | 2000-07-28 | 2005-01-24 | Henkel Kommanditgesellschaft Auf Aktien | Novel amylolytic enzyme extracted from bacillus sp. a 7-7 (dsm 12368) and washing and cleaning agents containing this novel amylolytic enzyme |
EP3088503B1 (en) * | 2015-04-29 | 2018-05-23 | The Procter and Gamble Company | Method of treating a fabric |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1056187C (en) * | 1988-02-11 | 2000-09-06 | 金克克国际有限公司 | Proteolytic enzymes and their use in detergents |
DK316989D0 (en) * | 1989-06-26 | 1989-06-26 | Novo Nordisk As | ENZYMES |
EP0405901B1 (en) * | 1989-06-26 | 2004-09-01 | Unilever Plc | Enzymatic detergent compositions |
DE69028890T2 (en) * | 1989-08-11 | 1997-02-27 | Gist Brocades Nv | Efficient production of protease mutants |
DE4023458A1 (en) * | 1989-08-31 | 1991-03-07 | Kali Chemie Ag | NEW HIGH ALKALINE PROTEASES |
DE4106525A1 (en) * | 1991-03-01 | 1992-09-10 | Solvay Enzymes Gmbh & Co Kg | METHOD FOR IMPROVING THE STABILITY OF HIGH ALKALINE PROTEASES |
EP0995801A1 (en) * | 1991-07-27 | 2000-04-26 | Genencor International GmbH | Process for increasing the stability of enzymes and stabilized enzymes |
-
1993
- 1993-02-12 DE DE19934304161 patent/DE4304161A1/en not_active Withdrawn
-
1994
- 1994-02-03 EP EP9494101624A patent/EP0610808A3/en not_active Ceased
- 1994-02-10 JP JP1656694A patent/JPH06296487A/en active Pending
- 1994-02-10 MX MX9401068A patent/MX9401068A/en unknown
- 1994-02-10 BR BR9400486A patent/BR9400486A/en not_active Application Discontinuation
- 1994-02-11 FI FI940647A patent/FI940647A/en unknown
- 1994-02-11 CA CA 2115465 patent/CA2115465A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP0610808A3 (en) | 1994-11-02 |
BR9400486A (en) | 1994-09-27 |
EP0610808A2 (en) | 1994-08-17 |
FI940647A (en) | 1994-08-13 |
FI940647A0 (en) | 1994-02-11 |
JPH06296487A (en) | 1994-10-25 |
DE4304161A1 (en) | 1994-08-25 |
MX9401068A (en) | 1994-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5453372A (en) | Stabilized enzymes and process for preparing them | |
DK175576B1 (en) | subtilisin | |
CA2016211C (en) | Multiply mutated subtilisins | |
AU705385B2 (en) | Use of alkaline proteases in commercial laundry methods | |
US5352603A (en) | Highly alkaline proteases | |
EP0328229B1 (en) | Novel proteolytic enzymes and their use in detergents | |
US5801039A (en) | Enzymes for detergents | |
US5741694A (en) | Useful mutations of bacterial alkaline protease | |
KR100196785B1 (en) | Novel highly alkaline prroteases | |
US6271012B1 (en) | Protease muteins and their use in detergents | |
JP2000210081A (en) | Heat-resistant alkali cellulase gene | |
US5252478A (en) | Thermostable mutants of neutral protease and means for their preparation | |
EP0416967B1 (en) | Novel alkaline protease | |
CA2115465A1 (en) | Highly alkaline proteases, dna sequences encoding them and process for their production | |
ITMI940779A1 (en) | MUTANTS OF THE NEUTRAL PROTEASIS AND MEANS AND METHODS FOR THEIR PREPARATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |